

業 績

論文数・IF(impact factor)値・CI(Citation index)値

OA 時期	論文数	IF	IF/論文数	CI	CI/論文数
1992- 2024	307	1453.9	4.74	2880	9.38
1992- 2013	106	645.8	6.09	1838	17.3
2014- 2024	201	808.1	4.02	1042	5.18
review 時期	論文数	IF	IF/論文数	CI	CI/論文数
1992- 2024	10	40.7	4.07	127	12.7
1992- 2013	1	x	x	5	X
2014- 2024	9	30.7	3.41	122	13.6
CR 時期	論文数	IF	IF/論文数	CI	CI/論文数
1992- 2024	36	80.3	2.23	71	1.97
1992- 2013	11	33.6	3.05	40	3.63
2014- 2024	26	48.3	1.86	31	1.19
Total 時期	論文数	IF	IF/論文数	CI	CI/論文数
1992- 2024	354	1576.5	4.45	3078	8.69

1992- 2013	118	679.4	5.78	1883	16
2014- 2024	236	887.1	3.76	1195	5.06

2014-2024 年は教授就

任後

I. Original Articles

8. **Shinohara N**, Ogiso Y, Kuzumaki N, Mullauer L, Katabami M, Togashi M, Koyanagi T: Circumvention of cisplatin resistance in H-ras transformed-NIH/3T3 cells by suppressor mutant of H-ras. *Int. J. Oncol.* 1, 93-96, 1992 [IF 5.2, CI 0]
9. Togashi M, **Shinohara N**, Toyota K, Koyanagi T, Maru A, Fujieda J, Kawakura K, Nishida T, Ohhashi N: Prophylactic chemotherapy for primary and recurrent superficial bladder cancer: preliminary results. The Hokkaido University Bladder Cancer Collaborating Group. *Cancer Chemother. Pharmacol.* 30, 21-25, 1992 [IF 3.0, CI 0]
10. **Shinohara N**, Liebert M, Wedemeyer G, Chang JHC, Grossman HB: Evaluation of multiple drug resistance in human bladder cancer cell lines. *J. Urol.* 150, 505-509, 1993 [IF 6.6, CI 8]
11. **Shinohara N**, Ogiso Y, Arai T, Takami S, Nonomura K, Koyanagi T, Kuzumaki N: Differential Na⁺, K⁺-ATPase activity and cisplatin sensitivity between transformants induced by H-ras and those induced by K-ras. *Int. J. Cancer* 58, 672-677, 1994 [IF 6.4, CI 3]
12. **Shinohara N**, Nonomura K, Takakura F, Hamada M, Grossman HB, Koyanagi T: Expression of multidrug resistance gene product (P-glycoprotein) in transitional cell carcinomas of the upper urinary tract. *Eur. Urol.* 26, 327-333, 1994. [IF 23.4, CI 0]
13. **Shinohara N**, Nonomura K, Tanaka M, Nagamori S, Takakura F, Seki T, Koyanagi T, Togashi M, Maru A: Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborating Group. *Cancer Chemothe. Pharmacol.* 35, 41-45, 1994 [IF 3.0, CI 3]
14. Park J, **Shinohara N**, Liebert M, Noto L, Flint A, Grossman HB: P-glycoprotein expression in bladder cancer. *J. Urol.* 151, 43-46, 1994 [IF 6.6, CI 3]
15. Arai T, Sagara M, **Shinohara N** : Changes of cytosolic enzyme activities in H-ras transformed NIH/3T3 cells. *Bull Nippon Vet. Anim. Sci. Univ.* 43, 49-51, 1994 [IF NA, CI 0]

16. **Shinohara N**, Nonomura K, Harabayashi T, Togashi M, Nagamori S, Koyanagi T: Nephron-sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. *J. Urol.* 154, 2016-2019, 1995 [IF 6.6, CI 2]
17. Kondo K, Sakai N, Kaneko S, Kobayashi K, Hosaka M, Ito S, Fujii S, Yamamoto I, Kim I, Miyagami M, Shidara N, **Shinohara N**, Koyanagi T, Kato N, Yamanaka H, Kurata JI, Fujioka M, Nakatsu H, Shimazaki J, Yoshida J, Sugita K, Hirao Y, Okajima E, Tanagawa T, Sato S, Fujino H, Nagata M, Kanayama H, Kagawa S, Yamashita T, Furuta T, Saito Y, Hara T, Murayama KI, Hiratsuka Y, Shimosegawa T, Maekawa M, Miyahara S, Murata K, Kawamura J, Ogawa O, Yoshida O, Miki M, Takeda N, Tanaka R, Kinoshita H, Sekine T, Yokota J, Kakizoe T, Kogawa T, Kanno H, Yao M, Shuin T: Germline mutations in the von Hippel-Lindau disease (VHL) gene in Japanese VHL. *Hum. Mol. Genet.* 4(12), 2233-2237, 1995 [IF 5.1, CI ?]
18. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, **Shinohara N**, Koyanagi T, Kuzumaki N: Gelsolin: a candidate for suppressor of human bladder cancer. *Cancer Res.* 55, 3228-3232, 1995 [IF 11.2, CI 40]
19. Demura T, **Shinohara N**, Tanaka M, Enami N, Chiba H, Togashi M, Ohashi N, Nonomura K, Koyanagi T: The Proportion of free to total prostate specific antigen: A method of detecting prostate carcinoma. *Cancer* 77, 1137-1143, 1996 [IF 6.2, CI 4]
20. **Shinohara N**, Ogiso Y, Tanaka M, Sazawa A, Harabayashi T, Koyanagi T: The significance of ras guanine nucleotide exchange factor, son of sevenless protein, in renal cell carcinoma cell lines. *J. Urol.* 158, 908-911, 1997 [IF 6.6, CI 2]
21. **Shinohara N**, Demura T, Matsumura K, Toyoda K, Kashiwagi A, Nagamori S, Ohmuro H, Ohzono S, Koyanagi T: 5-Fluorouracil and low-dose recombinant interferon a-2a in patients with hormone-refractory adenocarcinoma of the prostate. *Prostate* 35, 56-62, 1998 [IF 2.8, CI 1]
22. **Shinohara N**, Hioka T, Harabayashi T, Demura T, Kashiwagi A, Nagamori S, Koyanagi T: Treatment of metastatic nonseminomatous germ cell tumors of the testis: significance of the international consensus prognostic classification as a prognostic factor-based staging system. *Int. J. Urol.* 5(6), 562-567, 1998. [IF 2.6, CI 0]

23. Tanaka M, Sazawa A, **Shinohara N**, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N: Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. *Cancer Gene Ther.* 5, 482-487, 1999 [IF 6.4, CI 1]
24. Watanabe T, **Shinohara N**, Sazawa A, Kobayashi Y, Ogiso Y, Kimura T, Takeguchi M, Yasuda J, Hashimoto A, Koyanagi T, Kuzumaki N: Suppressive effects of dominant negative ras mutant N116Y on transformed phenotypes of human bladder cancer cells. *Cancer Letter* 149, 195-202, 2000 [IF 9.7, CI 2]
25. Kitta T, **Shinohara N**, Shirato H, Otsuka H, Koyanagi T: The treatment of chronic radiation proctitis with hyperbaric oxygen in patients with prostate cancer. *BJU Int.* 85(3), 372-374, 2000 [IF 4.5, CI 6]
26. Kitamura K, Shirato H, Suzuki K, **Shinohara N**, Demura T, Harabayashi T, Nishioka T, Kagei K, Takayama N, Shinno Y, Kawakura K, Koyanagi T, Miyasaka K.: The relationship between technical parameters of external beam radiation therapy and complications for localized prostate cancer. *Jpn. J. Clin. Oncol.* 30(5), 225-229, 2000 [IF 2.4, CI 1]
27. Watanabe T, **Shinohara N**, Moriya K, Sazawa A, Kobayashi Y, Ogiso Y, Takiguchi M, Yasuda J, Koyanagi T, Kuzumaki N, Hashimoto A: Significance of the Grb2 and son of sevenless (Sos) proteins in human bladder cancer cell lines. *IUBMB Life* 49(4), 317-320, 2000 [IF 4.6, CI 11]
28. Shirato H, Shimizu S, Kitamura K, Nishioka T, Kagei K, Hashimoto S, Aoyama H, Kunieda T, **Shinohara N**, Dosaka-Akita H, Miyasaka K: Four-dimensional treatment planning and fluoroscopic real-time tumor tracking radiotherapy for moving tumor. *Int. J. Radiat. Oncol. Biol. Phys.* 48(2), 435-442, 2000 [IF 7.0, CI 69]
29. Shimizu S, Shirato H, Kitamura K, **Shinohara N**, Harabayashi T, Tsukamoto T, Koyanagi T, Miyasaka K: Use of an implanted marker and real-time tracking of the marker for the positioning of prostate and bladder cancers. *Int. J. Radiat. Oncol. Biol. Phys.* 48(5), 1591-1597, 2000 [IF 7.0, CI 30]
30. Watanabe T, **Shinohara N**, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF: An

improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. *Cancer Gene Ther* 7(12), 1575-1580, 2000. [IF 6.4, CI 24]

31. **Shinohara N**, Harabayashi T, Sato S, Hioka T, Tsuchiya K, Koyanagi T: Impact of nephron-sparing surgery on quality of life in patients with localized renal cell carcinoma. *Eur. Urol.* 39(1), 114-119, 2001 [IF 23.4, CI 15]
32. Nonomura K, Koyama T, Kakizaki H, Murakumo M, **Shinohara N**, Koyanagi T: Testicular-sparing surgery for the prepubertal testicular tumor. Experience of two cases with large cell calcifying Sertoli cell tumors. *Eur. Urol.* 40(6), 699-704, 2001 [IF 23.4, CI 5]
33. Watanabe T, **Shinohara N**, Sazawa A, Takimoto M, Hashimoto A, Koyanagi T, Kuzumaki N: Adenovirus-mediated gene therapy for bladder cancer in an orthotopic model using a dominant negative H-ras mutant. *Int. J. Cancer* 92(5), 712-717, 2001 [IF 6.4, CI 3]
34. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, Shimizu S, **Shinohara N**, Harabayashi T, Miyasaka K: Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. *Int. J. Radiat. Oncol. Biol. Phys.* 53(5), 1117-1123, 2002 [IF 7.0, CI 49]
35. Kitamura K, Shirato H, Shimizu S, **Shinohara N**, Harabayashi T, Shimizu T, Kodama Y, Endo H, Onimaru R, Nishioka S, Aoyama H, Tsuchiya K, Miyasaka K: Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). *Radiother. Oncol.* 62(3), 275-281, 2002 [IF 5.7, CI 30]
36. Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, **Shinohara N**, Koyanagi T, Kuzumaki N: Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. *J Urol* 168(3), 1182-1187, 2002 [IF 6.6 CI 4]
37. Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, **Shinohara N**, Katoh C, Nakada K, Tamaki N: Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* 29(11), 1492-1495, 2002 [IF 9.1 CI 39]
38. Suzuki S, **Shinohara N**, Harabayashi T, Taniguchi A, Haga K, Sato S, Sakamoto K,

- Koyanagi T: Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. *Int. J. Clin. Oncol.* 7(5), 289-293, 2002 [IF 3.3 CI 1]
39. Shirato H, Harada T, Harabayashi T, Hida K, Endo H, Kitamura K, Onimaru R, Yamazaki K, Kurauchi N, Shimizu T, **Shinohara N**, Matsushita M, Dosaka-Akita H, Miyasaka K.: Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. *Int. J. Radiat. Oncol. Biol. Phys.* 56(1), 240-247, 2003 [IF 7.0 CI 88]
40. Kitamura K, Shirato H, **Shinohara N**, Harabayashi T, Onimaru R, Fujita K, Shimizu S, Nonomura K, Koyanagi T, Miyasaka K.: Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study. *Cancer J.* 9(4), 268-276, 2003 [IF 2.2 CI 13]
41. Harabayashi T, **Shinohara N**, Katano H, Nonomura K, Shimizu T, Koyanagi T: Management of renal angiomyolipomas associated with tuberous sclerosis complex. *J. Urol.* 171(1), 102-105, 2004 [IF 6.6 CI 23]
42. Sato S, **Shinohara N**, Suzuki S, Harabayashi T, Koyanagi T: Multiple primary malignancies in Japanese patients with renal cell carcinoma. *Int. J. Urol.* 11(5), 269-275, 2004 [IF 2.6 , CI 19]
43. Taniguchi A, Tajima T, Nonomura K, **Shinohara N**, Mikami A, Koyanagi T: Expression of vascular endothelial growth factor and its receptors Flk-1 and Flt-1 during the regeneration of autotransplanted adrenal cortex in the adrenalectomized rat. *J. Urol.* 171(6), 2445-2449, 2004 [IF 6.6 CI 3]
44. Takahashi A, Tsukamoto T, Tobisu K, **Shinohara N**, Sato K, Tomita Y, Komatsubara S, Nishizawa O, Igarashi T, Fujimoto H, Nakazawa H, Komatsu H, Sugimura Y, Ono Y, Kuroda M, Ogawa O, Hirao Y, Hayashi T, Tsushima T, Kakehi Y, Arai Y, Ueda S, Nakagawa M: Radical cystectomy for invasive bladder cancer: results of multi-institutional pooled analysis. *Jpn. J. Clin. Oncol.* 34(1), 14-19, 2004 [IF 2.4 CI 9]
45. Chen Q, **Shinohara N**, Abe T, Watanabe T, Nonomura K, Koyanagi T.: Significance of

- COX-2 expression in human renal cell carcinoma cell lines. *Int J Cancer*. 108(6), 825-32, 2004 [IF 6.4 CI 13]
46. Furuno T, Demura T, Kaneta T, Gotoda H, Muraoka S, Sato T, Nagamori S, **Shinohara N**, Koyanagi T: Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. *Prostate* 58(1), 76-81, 2004 [IF 2.8 CI 21]
47. Suzuki S, **Shinohara N**, Harabayashi T, Sato S, Abe T, Koyanagi T: Impact of adjuvant systemic chemotherapy on postoperative survival in patients with high-risk urothelial cancer. *Int J. Urol.* 11(7), 456-460, 2004 [IF 2.6 CI 6]
48. Haga K, Fujita H, Nomoto M, Sazawa A, Nakagawa K, Harabayashi T, **Shinohara N**, Takimoto M, Nonomura K, Kuzumaki N: Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO₄ in vivo footprinting on its promoter region. *Int. J. Cancer* 111(6), 873-880, 2004 [IF 6.4, CI 4]
49. Chen Q, **Shinohara N**, Abe T, Harabayashi T, Nonomura K: Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. *J. Urol.* 172 (6), 2153–2157, 2004 [IF 6.6 CI 9]
50. Hachiya T, Akakura K, Saito S, **Shinohara N**, Sato K, Harada M, Kato T, Okada K: A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan. *BJU Int.* 95(4), 534-540. 2005 [IF 4.5 CI 4]
51. Demura T, Hioka T, Furuno T, Kaneta T, Gotoda H, Muraoka S, Sato T, Mochizuki T, Nagamori S, **Shinohara N**: Differences in tumor core distribution between palpable and nonpalpable prostate tumors in patients diagnosed using extensive transperineal ultrasound-guided template prostate biopsy. *Cancer* 103(8), 1826-1832, 2005 [IF 6.2 , CI 16]
52. Minami K, Yanagawa Y, Iwabuchi K, **Shinohara N**, Harabayashi T, Nonomura K, Onoe K: Negative feed back regulation of T helper type 1 (Th1)/Th2 cytokine balance via dendritic cell and natural killer T cell interactions. *Blood* 106(5), 1685-1693, 2005 [IF 20.3 , CI 11]
53. **Shinohara N**, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K: Salvage chemotherapy with

- paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. *Cancer Chemother. Pharmacol.* 58(3), 402-407, 2006 [IF 3, CI 10]
54. Abe T, Tada M, **Shinohara N**, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi T, Nonomura K. : Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice. *Int. J. Urol.* 13(1), 47-57, 2006 [IF 2.6 CI 10]
55. Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, **Shinohara N**, Shinka T, Tachibana M, Naito S, Hirao Y: BCG Tokyo 172 Strain Study Group. Sustained prophylactic effect of intravesical bacille Calmette-Guerin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study. *Urology* 67(3), 545-549, 2006 [IF 2.1 CI 5]
56. Toyoda Y, **Shinohara N**, Harabayashi T, Abe T, Akino T, Sazawa A, Nonomura K: Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. *Eur. Urol.* 52(1), 163-168, 2007 [IF 23.4 CI 21]
57. Higashiyama H, Harabayashi T, **Shinohara N**, Chuma M, Hige S, Nonomura K.: Reactivation of Hepatitis in a Bladder Cancer Patient Receiving Chemotherapy. *Int. Urol. Nephrol.* 39(2), 461-463, 2007 [IF 2 CI 3]
58. Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Maruyama S, Suzuki S, Nonomura K. : Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer. *Eur. Urol.* 52 (4), 1106-1113, 2007 [IF 23.4, CI 23]
59. Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Suzuki S, Kawarada Y, Nonomura K. : Postoperative inguinal hernia after radical prostatectomy for prostate cancer. *Urology* 69(2), 326-329, 2007 [IF 2.1, CI 22]
60. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, Saito Y, Tobisu K, Kakizoe T, Shibata T, Fukuda H, Akakura K, Suzuki H, **Shinohara N**, Egawa S, Irie A, Sato T, Maeda O, Meguro N, Sumiyoshi Y, Suzuki T, Shimizu N, Arai Y, Terai A, Kato T, Habuchi T, Fujimoto H, Niwakawa M: Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer. *Jpn. J. Clin.*

Oncol. 38(2), 122-128, 2008 [IF 2.4, CI 31]

61. Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, **Shinohara N**, Nonomura K, Hatakeyama S: TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells. *Cancer Res.* 68 (9), 3486-3494, 2008 [IF 11.2, CI 27]
62. Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Ishikawa S, Kubota K, Matsuno Y, Osawa T, Shibata T, Shinno Y, Kamoto S, Minami K, Sakashita S, Takeuchi I, Kumagai A, Mori T, Togashi M, Nonomura K: The Role of Lymph Node Dissection in the Treatment of Upper Urinary Tract Cancer: Multi-institutional study. *BJU Int.* 102(5), 576-80, 2008 [IF 4.5, CI 13]
63. Abe T, **Shinohara N**, Tada M, Harabayashi T, Sazawa A, Maruyama S, Moriuchi T, Takeda K, Nonomura K: Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers. *Int. J. Urol.* 15(5), 429-434, 2008 [IF 2.6, CI 4]
64. Katoh N, Onimaru R, Sakuhara Y, Abo D, Shimizu S, Taguchi H, Watanabe Y, **Shinohara N**, Ishikawa M, Shirato H: Real-time tumor-tracking radiotherapy for adrenal tumors. *Radiother. Oncol.* 87(3), 418-424, 2008 [IF 5.7, CI 20]
65. Ito K, Nakazawa H, Marumo K, Ozono S, Igarashi T, **Shinohara N**, Fukuda M, Tsushima T, Naito S, Hayakawa M: Risk factors for ipsilateral adrenal involvement in renal cell carcinoma. *Urology* 72(2), 354-358, 2008 [IF 2.1, CI 2]
66. Hinotsu S, Akaza H, Miki T, Fujimoto H, **Shinohara N**, Kikuchi E, Mizutani Y, Koga H, Okajima E, Okuyama A; Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. *Int. J. Urol.* 16(1), 64-69, 2009 [IF 2.6, CI 1]
67. Osawa T, Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Kubota K, Matsuno Y, Shibata T, Shinno Y, Kamoto S, Minami K, Sakashita S, Kumagai A, Mori T, Nonomura K: Role of lymph node density in predicting survival of patients with lymph node metastases after radical cystectomy: A multi-institutional study. *Int. J. Urol.* 16(3), 274-278, 2009 [IF 2.6, CI 15]
68. Kikuchi E, Fujimoto H, Mizutani Y, Okajima E, Koga H, Hinotsu S, **Shinohara N**, Oya M,

Miki T; the Cancer Registration Committee of the Japanese Urological Association: Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association. *Int. J. Urol.* 16(3), 279-286, 2009 [IF 2.6, CI 16]

69. **Shinohara N**, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A, Nonomura K : Multi-center phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon alfa for metastatic renal cell carcinoma. *Jpn. J. Clin. Oncol.* 39(11), 720-726, 2009 [IF 2.4, CI 9]
70. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, **Shinohara N**, Nonomura K, Klagsbrun M, Shindoh M: Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors. *Am. J. Pathol.* 175(6), 2657-2667, 2009 [IF 6.0, CI 94]
71. Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Akino T, Ishikawa S, Kubota K, Matsuno Y, Osawa T, Shibata T, Toyoda Y, Shinno Y, Kamota S, Minami K, Sakashita S, Kumagai A, Takada N, Togashi M, Sano H, Mori T, Nonomura K: Pathologic characteristics and clinical course of bladder tumor developing after nephroureterectomy. *BJU Int.* 105(8), 1102-1106, 2010 [IF 4.5, CI 3]
72. Naito S, Yamamoto N, Takayama T, Muramoto M, **Shinohara N**, Nishiyama K, Takahashi A, Maruyama R, Saika T, Hoshi S, Nagao K, Yamamoto S, Sugimura I, Uemura H, Koga S, Takahashi M, Ito F, Ozono S, Terachi T, Naito S, Tomita Y: Prognosis of Japanese Metastatic Renal Cell Carcinoma Patients in the Cytokine Era: A Cooperative Group Report of 1463 Patients. *Eur. Urol.* 57(2), 317-325, 2010 [IF 23.4, CI 72]
73. Uemura H, **Shinohara N**, Yuasa T, Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H: A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. *Jpn. J. Clin. Oncol.* 40(3), 194-202, 2010 [IF 2.4, CI 56]
74. Yokomizo A, Koga H, **Shinohara N**, Miyahara T, Machida N, Hasui Y, Uozumi J, Nishiyama K, Satoh F, Sakai H, Naito S: Skeletal-related events in urological cancer patients with bone metastasis: A multicenter study in Japan. *Int. J. Urol.* 17(4), 332-336, 2010 [IF 2.6, CI 4]

75. Oishi Y, Nagai S, Yoshida M, Fujisawa SI, Sazawa A, **Shinohara N**, Nonomura K, Matsuno K, Shimizu C.: Mutation analysis of the SDHB and SDHD genes in pheochromocytomas and paragangliomas: identification of a novel nonsense mutation (Q168X) in the SDHB gene. *Endocr. J.* 57(8), 745-750, 2010 [IF 2.0, CI 4]
76. Tsuchiya K, Hida K, Hida Y, Muraki C, Ohga N, Akino T, Kondo T, Miseki T, Nakagawa K, Shindoh M, Harabayashi T, **Shinohara N**, Nonomura K, Kobayashi M: Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. *Int. J. Oncol.* 36(6), 1379-1386, 2010 [IF 5.2, CI 20]
77. Sumiyoshi Y, Hashine K, Kakehi Y, Yoshimura K, Satou T, Kuruma H, Namiki S, **Shinohara N**: Dietary administration of mushroom mycelium extracts in patients with early stage prostate cancers managed expectantly: A phase II study. *Jpn. J. Clin. Oncol.* 40(10), 967-972, 2010 [IF 2.4, CI 4]
78. Ishikawa S, Abe T, **Shinohara N**, Harabayashi T, Sazawa A, Maruyama S, Kubota K, Matsuno Y, Osawa T, Shinno Y, Kumagai A, Togashi M, Matsuda H, Mori T, Nonomura K: Impact of Diagnostic Ureteroscopy on Intravesical Recurrence and Survival in Patients with Upper Urinary Tract Cancer. *J. Urol.* 184(3), 883-888, 2010 [IF 6.6, CI 28]
79. Tomita Y, **Shinohara N**, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H: Overall survival and updated results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. *Jpn. J. Clin. Oncol.* 40(12). 1166-1172, 2010 [IF 2.4, CI 50]
80. Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S, **Shinohara N**, Sazawa A, Fukushima S, Naito S: Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. *J. Endourol.* 24(11), 1807-1811, 2010 [IF 2.7, CI 32]
81. Abe T, **Shinohara N**, Muranaka M, Sazawa A, Maruyama S, Osawa T, Harabayashi T, Kubota K, Matsuno Y, Shibata T, Toyada Y, Shinno Y, Minami K, Sakashita S, Kumagai A, Takada N, Togashi M, Sano H, Mori T, Nonomura K.: Role of lymph node dissection in the

treatment of urothelial carcinoma of the upper urinary tract: Multi-institutional relapse analysis and immunohistochemical re-evaluation of negative lymph nodes. *Eur. J. Surg. Oncol.* 36(11), 1085-1091. 2010 [IF 3.8, CI 23]

82. Naito S, Eto M, **Shinohara N**, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T, Akaza H: Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. *J. Clin. Oncol.* 28, 5022-5028, 2010 [IF 45.3, CI 1]

83. Tsukamoto T, **Shinohara N**, Tsuchiya N, Hamamoto Y, Maruoka M, Fujimoto H, Niwakawa M, Uemura H, Usami M, Terai A, Kanayama H, Sumiyoshi Y, Eto M, Tajima T, Kasuga A, Fujita Y, Kay A, Akaza H: Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients From RECORD-1. *Jpn. J. Clin. Oncol.* 41, 17-24, 2010 [IF 2.4, CI 17]

84. Okajima E, Fujimoto H, Mizutani Y, Kikuchi E, Koga H, Hinotsu S, **Shinohara N**, Miki T: the Cancer Registration Committee of the Japanese Urological Association. : Cancer death from non-muscle invasive bladder cancer: Report of the Japanese Urological Association of data from the 1999-2001 registry in Japan. *Int. J. Urol.* 17(11) 905-912, 2010 [IF 2.6, CI 1]

85. **Shinohara N**, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K: The incidence and the mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma. *Br. J. Cancer* 104, 241-247, 2011 [IF 8.8, CI 17]

86. Miyao N, Naito S, Ozono S, **Shinohara N**, Masumori N, Igarashi T, Nakao M, Tsushima T, Senga Y, Horie S, Kanayama HO, Tokuda N, Kobayashi M; Japanese Society of Renal Cancer: Late Recurrence of Renal Cell Carcinoma: Retrospective and Collaborative Study of the Japanese Society of Renal Cancer. *Urology* 77, 379-384, 2011 [IF 2.1, CI 32]

87. Abe T, Harabayashi T, **Shinohara N**, Sazawa A, Maruyama S, Sasaki H, Nonomura K.: Outcome of Regional Lymph Node Dissection in Conjunction with Laparoscopic Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract. *J. Endourol.* 25(5), 803-807, 2011 [IF 2.7, CI 2]

88. Shimizu S, Osaka Y, **Shinohara N**, Sazawa A, Nishioka K, Suzuki R, Onimaru R, Shirato H.: Use of Implanted Markers and Interportal Adjustment with Real-Time Tracking

- Radiotherapy System to Reduce Intrafraction Prostate Motion. *Int J Radiat Oncol Biol Phys.* 81(4), e393-399, 2011 [IF 7.0, CI 14]
89. Tomita Y, Uemura H, Fujimoto H, Kanayama H, **Shinohara N**, Nakazawa H, Imai K, Umeyama Y, Ozono S, Naito S, Akaza H: Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell cancer. *Eur. J. Cancer* 47(17), 2592-2602, 2011 [IF 8.4, CI 51]
90. Maru S, Abe T, **Shinohara N**, Sazawa A, Maruyama S, Harabayashi T, Suzuki S, Nonomura K: Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: A retrospective study. *Int J Urol* 19(2), 110-116, 2012 [IF 2.6, CI 10]
91. **Shinohara N**, Abe T, Sazawa A, Maruyama S, Shindo J, Sato S, Suzuki S, Nonomura K: Interferon- α -based immunotherapy in metastatic renal cell carcinoma patients with the primary tumor in situ. *Jpn. J. Clin. Oncol.* 42(2), 113-119, 2012 [IF 2.4, CI 2]
92. Saito H, Matsuda T, Tanabe K, Kawauchi A, Terachi T, Nakagawa K, Iwamura M, Shigeta M, Naito S, Ito A, Machida J, Kawakita M, Kinoshita H, **Shinohara N**, Ioritani N, Seki T, and Arai Y, on behalf of the Japanese Society of Endourology Laparoscopic Partial Nephrectomy Study Group. Surgical and oncological outcomes of laparoscopic partial nephrectomy: a Japanese multi-institutional study of 1,375 patients. *J. Endourol.* 26(6), 652-659, 2012 [IF 2.7, CI 4]
93. Ohga N, Ishikawa S, Maishi N, Akiyama K, Hida Y, Kawamoto T, Sadamoto Y, Osawa T, Yamamoto K, Kondoh M, Ohmura H, **Shinohara N**, Nonomura K, Shindoh M, Hida K: Heterogeneity of Tumor Endothelial Cells: Comparison between Tumor Endothelial Cells Isolated from Highly Metastatic and Low Metastatic Tumors. *Am. J. Pathol.* 180(3), 1294-1307, 2012 [IF 6.0, CI 73]
94. Maishi N, Ohga N, Hida Y, Akiyama K, Kitayama K, Osawa T, Onodera Y, **Shinohara N**, Nonomura K, Shindoh M, Hida K: CXCR7: A novel tumor endothelial marker in renal cell carcinoma. *Pathol. Int.* 62(5), 309-317, 2012 [IF 2.2, CI 39]
95. Yamamoto K, Ohga N, Hida Y, Maishi N, Kawamoto T, Kitayama K, Akiyama K, Osawa T,

- Kondoh M, Matsuda K, Onodera Y, Fujie M, Kaga K, Hirano S, **Shinohara N**, Shindoh M, Hida K: Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. *Br. J. Cancer* 106(6), 1214-1223, 2012 [IF 8.8, CI 55]
96. Osawa T, Ohga N, Hida Y, Kitayama K, Akiyama K, Onodera Y, Fujie M, **Shinohara N**, Nonomura K, Shindoh M, Hida K: Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner. *Cancer Sci.* 103(6), 1038-1044, 2012 [IF 5.7, CI 17]
97. **Shinohara N**, Nonomura K, Abe T, Maruyama S, Kamai T, Takahashi M, Tatsugami K, Yokoi S, Deguchi T, Kanayama H, Oba K, Naito S: A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. *Cancer Sci.* 103 (9), 1695-1700, 2012 [IF 5.7, CI 20]
98. Mitsui T, Tanaka H, Harabayashi T, Moriya K, Maruyama S, Abe T, Sazawa A, **Shinohara N**, Nonomura K: Changes in urodynamics and lower urinary tract symptoms after radical prostatectomy: implications of preoperative detrusor. contractility. *LUTS* 2012; 4: 82-86, 2012 [IF 1.3, CI 0]
99. Abe T, Sazawa A, Harabayashi T, **Shinohara N**, Maruyama S, Nonomura K: Renal hypothermia with ice slush in laparoscopic partial nephrectomy: the outcome of renal function. *J. Endourol.* 26(11), 1483-1488, 2012 [IF 2.7, CI 6]
100. Kuroda N, Tanaka A, Yamaguchi T, Kasahara K, Naruse K, Yamada Y, Chikai-Kubota K, **Shinohara N**, Nagashima Y, Mikami S, Oya M, Hamashima T, Michal M, Hes O: Chromophobe renal cell carcinoma, oncocytic variant: A proposal of a new variant and a critical diagnostic pitfall in diagnosing renal oncocytic tumors. *Med. Mol. Morphol.* 46(1), 49-55, 2013 [IF 1.8, CI 18]
101. Takada N, Abe T, **Shinohara N**, Sazawa A, Maruyama S, Shinno Y, Sato S, Mitsuhashi K, Sato T, Sugishita K, Kamota S, Yamashita T, Ishizaki J, Hioka T, Mouri G, Ono T, Miyajima N, Sakuta T, Mochizuki T, Aoyagi T, Katano H, Akino T, Hirakawa K, Minami K, Kumagai A, Seki T, Togashi M, Nonomura K: Perioperative Morbidity and Mortality related to Radical Cystectomy – A Multi-institutional Retrospective Study in Japan. *BJU Int.* 2012 Dec;110(11 Pt B):E756-64. [IF 4.5, CI 20]
102. Kunieda F, Kitamura H, Niwakawa M, Kuroiwa K, **Shinohara N**, Tobisu K,

- Nakamura K, Shibata T, Tsuzuki T, Tsukamoto T, Kakehi Y, and Urological Oncology Study Group of the Japn Clinical Oncology Group: Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology in the second transurethral resection: Japan Clinical Oncology Group Study JCOG1019. *Jpn. J. Clin. Oncol.* 42(11), 1094-1098, 2012 [IF 2.4, CI 6]
103. Takeda N, Isu K, Hiraga H, **Shinohara N**, Minami A, Kamata H: Radiotherapy with zoledronic acid for bone metastases from renal cell carcinoma: More than a 24-month median follow-up. *J. Orthop. Sci.* 17(6), 770-774, 2012 [IF 1.7, CI 6]
104. Maru S, Ishigaki Y, **Shinohara N**, Takata T, Tomosugi N, Nonomura K: Efficacy of ATP-competitive inhibitors of mTORC2 on regulation of E-cadherin via HIF-2 α in the renal cell carcinoma cell line 786-O. *J. Urol.* 189(5), 1921-1929, 2013 [IF 6.6, CI 15]
105. Akiyama K, Ohga N, Maishi N, Hida Y, Kitayama K, Kawamoto T, Osawa T, Suzuki Y, **Shinohara N**, Nonomura K, Shindoh M, Hida K.: The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. *Pathol. Int.* 63(1), 37-44, 2013 [IF 2.2, CI 10]
106. Naito S, Kinoshita H, Kondo T, **Shinohara N**, Kasahara T, Saito K, Takayama T, Masumori N, Takahashi W, Takahashi M, Terachi T, Ozono S, Naito S, Tomita Y: Prognostic Factors of Metastatic Renal Cell Carcinoma Patients with Removed Metastases: A Multicentre Study of 559 Patients. *Urology* 82(4), 846-851, 2013 [IF 2.1, CI 20]
107. **Shinohara N**, Maruyama S, Shimizu S, Nishioka K, Abe T, Hatanaka K, Oba K, Nonomura K, Shirato H: Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. *J. Radiat. Res.* 54(6), 1095-1101, 2013 [IF 2.0, CI 8]
108. Osawa T, **Shinohara N**, Maruyama S, Oba K, Abe T, Maru S, Takada N, Sazawa A, Nonomura K: Long-term renal function outcomes in bladder cancer after radical cystectomy. *Urol. J.* 10(1), 784-789, 2013 [IF 1.5, CI 10]
109. Ueda T, Uemura H, Tomita Y, Tsukamoto T, Kanayama H, **Shinohara N**, Tarazi J, Chen C, Kim S, Ozono S, Naito S, Akaza H: Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from a randomized phase 3 AXIS trial. *Jpn. J. Clin. Oncol.* 43(6), 616-628, 2013 [IF 2.4, CI 42]

110. Osawa T, Ohga N, Hida Y, Kitayama K, Akiyama K, Onodera Y, Fujita M, **Shinohara N**, Nonomura K, Shindoh M, Hida K: Lysyl oxidase secreted by tumor endothelial cells promotes angiogenesis and metastasis. *Br J Cancer* 109(8), 2237-2247, 2013 [IF 8.8, CI 45]
111. **Shinohara N**, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa A, Oba K, Nonomura K: Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? *Urol. Oncol.* 31(7), 1276-1282, 2013 [IF 2.7, CI 12]
112. Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, **Shinohara N**, Nonomura K, Neckers L.: The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven tumor models. *Cancer Res.* 73(23), 7022-7033, 2013 [IF 11.2, CI 30]
113. Hirono M, Kobayashi M, Tsushima T, Obara W, **Shinohara N**, Ito K, Eto M, Takayama T, Fujii Y, Nishikido M, Kimura G, Kishida T, Takahashi M, Miyao N, Naya Y, Abe T, Fujioka T, Ito K, Naito S.: Impacts of clinicopathologic and operative factors on short-term and long-term survival in renal cell carcinoma with venous tumor thrombus extension before introducing molecular-targeted therapy: a multi-institutional retrospective study in Japan. *BMC Cancer.* 13, 447, 2013. doi: 10.1186/1471-2407-13-447 [IF 3.8, CI 18]
114. Nishioka K, Shimizu S, **Shinohara N**, Ito YM, Abe T, Maruyama S, Kinoshita R, Harada K, Nishikawa N, Miyamoto N, Onimaru R, Shirato H: Prospective Phase II study of image-guided local boost radiotherapy using a real-time tumor-tracking radiotherapy (RTRT) system for locally advanced bladder cancer. *Jpn J Clin Oncol.* 2014 Jan;44(1):28-35. [IF 2.4, CI 4]
115. **Shinohara N**, Nonomura N, Eto M, Kimura G, Minami H, Tokunaga S, Naito S. Arandomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skinreaction caused by sorafenib in patients with renal cell carcinoma. *Ann Oncol.* 2014 Feb;25(2):472-6. [IF 50.5, CI 14]
116. Abe T, Takada N, **Shinohara N**, Matsumoto R, Murai S, Sazawa A, Maruyama S

- Tsuchiya K, Kanzaki S, Nonomura K: A comparison of 90-day complications between ileal conduit and neobladder reconstruction after radical cystectomy – A retrospective multi-institutional study in Japan. *Int J Urol*. 2014 Jun;21(6):554-9. [IF 2.6, CI 17]
117. Abe T, Kitamura H, Tsukamoto T, Obara W, Fujioka T, Matsumura N, Hara I, **Shinohara N**, Nonomura K: Outcome of metastasectomy for urothelial carcinoma: A multi-institutional retrospective study. *J Urol*. 2014 Apr;191(4):932-6. [IF 6.6, CI 24]
118. Naito S, Tatsugami K, **Shinohara N**, Tomita Y, Mizokami A, Fijisawa M, Hashine K, Nishikido M, Nakagawa M, Tsukamoto T, Akaza H: Final results of phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma. *Jpn J Clin Oncol*. 2014 Feb;44(2):122-6. [IF 2.4, CI 1]
119. Matsumoto R, Abe T, **Shinohara N**, Murai S, Maruyama S, Tsuchiya K, Nonomura K: RENAL nephrometry score is a predictive factor for annual growth rate of renal mass. *Int J Urol*. 2014 Jun;21(6):549-52. [IF 2.6, CI 4]
120. Shimizu S, Nishioka K, Suzuki R, **Shinohara N**, Maruyama S, Abe T, Kinoshita R, Katoh N, Onimaru R, Shirato H: Early results of urethral dose reduction and small safety margin in intensity-modulated radiation therapy (IMRT) for localized prostate cancer using a real-time tumor-tracking radiotherapy (RTRT) system. *Radiat Oncol*. 2014 May 21;9:118. [IF 3.6, CI 0]
121. Otsubo T, Hida Y, Ohga N, Sato H, Kai T, Matsuki Y, Takasu H, Akiyama K, Maishi N, Kawamoto T, **Shinohara N**, Nonomura K, Hida K.: Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells. *Cancer Sci*. 2014 May;105(5):560-7. [IF 5.7, CI 18]
122. Alam MT, Nagao-Kitamoto H, Ohga N, Akiyama K, Maishi N, Kawamoto T, **Shinohara N**, Taketomi A, Shindoh M, Hida Y, Hida K. Suprabasin as a novel tumor endothelial cell marker. *Cancer Sci*. 2014 Dec;105(12):1533-40. [IF 5.7, CI 18]
123. Ara MN, Hyodo M, Ohga N, Akiyama K, Hida K, Hida Y, **Shinohara N**, Harashima H.: Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand. *Cancer Med*. 2014 Aug;3(4):825-34. [IF 4.0, CI 8]

124. Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, **Shinohara N**, Tatsugami K, Hinotsu S, Naito S; Japan RCC Trialist Collaborative Group (JRTCG) investigators.: Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. *BMC cancer* 2015; 15(1):667 [IF 3.8, CI 7]
125. Ohmura-Kakutani H, Akiyama K, Maishi N, Ohga N, Hida Y, Kawamoto T, Iida J, Shindoh M, Tsuchiya K, **Shinohara N**, Hida K. Identification of tumor endothelial cells with high aldehyde dehydrogenase activity and a highly angiogenic phenotype. *PLoS One*. 2014 Dec 1;9(12):e113910. doi: 10.1371/journal.pone.0113910 [IF 3.7, CI 35]
126. Abe T, Takada N, Matsumoto R, Osawa T, Sazawa A, Maruyama S, Tsuchiya K, Harabayashi T, Minami K, Nagamori S, Hatanaka KC, Tanaka Y, **Shinohara N**, Nonomura K. Outcome of regional lymphadenectomy in accordance with primary tumor location on laparoscopic nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study. *J Endourol*. 2015 Mar;29(3):304-9. [IF 2.7, CI 10]
127. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, Harada H, Tsujikawa K, Konishi N, **Shinohara N**, Nakajima Y. Clinical significance and therapeutic potential of prostate cancer antigen-1/ALKBH3 in human renal cell carcinoma. *Oncol Rep*. 2015 Aug;34(2):648-54. [IF 4.2, CI 12]
128. Kojima T, Kawai K, Tsuchiya K, Abe T, **Shinohara N**, Tanaka T, Masumori N, Yamada S, Arai Y, Narita S, Tsuchiya N, Habuchi T, Nishiyama H. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor. *Int J Urol*. 2015 Oct;22(10):923-7. [IF 2.6, CI 8]
129. Matsumoto R, Takada N, Abe T, Minami K, Harabayashi T, Nagamori S, Hatanaka KC, Miyajima N, Tsuchiya K, Maruyama S, Murai S, **Shinohara N**. Prospective mapping of lymph node metastasis in Japanese patients undergoing radical cystectomy for bladder cancer: characteristics of micrometastasis. *Jpn J Clin Oncol*. 2015 Sep;45(9):874-80. [IF 2.4, CI 3]
130. Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, Tanino M, Nishihara H, Hida K, Ohba Y, **Shinohara N**, Nonomura K, Tanaka S. Adaptor protein CRK induces

epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF/c-Met feedback loop. *Cancer Sci.* 2015 Jun;106(6):709-717. [IF 5.7, CI 23]

131. Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K, Morioka K, Kishi R, Shinohara N, Takeda M, Nonomura K. The Relationship between the Second-to-Fourth Digit Ratio and Behavioral Sexual Dimorphism in School-Aged Children. *PLoS One.* 2016 Jan 12;11(1):e0146849. [IF 3.7, CI 7]
132. Moriya K, Mitsui T, Kitta T, Nakamura M, Kanno Y, Kon M, Nishimura Y, **Shinohara N**, Nonomura K: Early Discontinuation of Antibiotic Prophylaxis in Patients with Persistent Primary Vesicoureteral Reflux Initially Detected during Infancy: Outcome Analysis and Risk Factors for Febrile Urinary Tract Infection. *J Urol* 2015, 193(2):637-642. [IF 6.6, CI 6]
133. Naito S, Sakai H, Hashine K, Tomita Y, **Shinohara N**, Fujisawa M, Eto M, Ozono S, Akaza H. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma. *Ann Oncol.* 2015 Sep;26(9):1871-1876. [IF 50.5, CI 1]
134. **Shinohara N**, Obara W, Tatsugami K, Naito S, Kamba T, Takahashi M, Murai S, Abe T, Oba K, Naito S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. *Cancer Sci.* 2015 May;106(5):618-26. [IF 5.7, CI 12]
135. Tatsugami K, **Shinohara N**, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S; Japanese Society of Renal Cancer. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. *Int J Urol.* 2015 Aug;22(8):736-40. [IF 2.6, CI 8]
136. Mitsui T, Kitta T, Moriya K, Takeda M, **Shinohara N**: Traumatic pediatric spinal cord injury: long-term outcomes of lower urinary tract function. *Spinal cord series and cases* 2015, 1:15023. [IF 1.2, CI 0]
137. Chiba H, Mitsui T, Kitta T, Ohmura Y, Moriya K, Kanno Y, Yoshioka M, **Shinohara N**. The role of serotonergic mechanism in the rat prefrontal cortex for controlling the micturition reflex: An in vivo microdialysis study. *Neurourol Urodyn.* 2016 Nov;35(8):902-907. [IF 2.0, CI 3]

138. Yokomizo A, Kanimoto Y, Okamura T, Ozono S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama HO, Akaza H, **Shinohara N**, Mugiya S, Nomata K, Nakamura T, Naito S. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. *J Urol*. 2016 Jan;195(1):41-6. [IF 6,6, CI 16]
139. Harada T, Abe T, Kato F, Matsumoto R, Fujita H, Murai S, Miyajima N, Tsuchiya K, Maruyama S, Kudo K, **Shinohara N**. Five-point Likert scaling on MRI predicts clinically significant prostate carcinoma. *BMC Urol*. 2015 Sep 4;15:91. [IF 2.0, CI 16]
140. Murahashi N, Abe T, Shinohara N, Murai S, Harabayashi T, Sazawa A, Maruyama S, Tsuchiya K, Miyajima N, Hatanaka K, Nonomura K. Diagnostic outcome of ureteroscopy in urothelial carcinoma of the upper urinary tract: Incidence of later cancer detection and its risk factors after the first examination. *BMC Urol*. 2015 Sep 4;15:92. [IF 2.0, CI 1]
141. Sasaki H, Wada H, Baghdadi M, Tsuji H, Otsuka R, Morita K, Shinohara N, Seino K. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts. *Transplantation*. 2015 Nov;99(11):2301-10. [IF 6.2, CI 11]
142. Kitta T, Chancellor MB, de Groat WC, **Shinohara N**, Yoshimura N: Role of the anterior cingulate cortex in the control of micturition reflex in a rat model of Parkinson's disease. *J Urol*. 2016; 195(5):1613-1620. [IF 6.6, CI 11]
143. Mitsui T, Moriya K, Morita K, Iwami D, Kitta T, Kanno Y, Takeda M, **Shinohara N**: Risk Factors for Lower Urinary Tract Dysfunction and Symptoms After Successful Renal Transplantation. *Ann Transplant*. 2015; 20:757-763. [IF 1.1, CI 1]
144. Abe T, Sazawa A, Harabayashi T, Oishi Y, Miyajima N, Tsuchiya K, Maruyama S, Okada H, **Shinohara N**: Laparoscopic resection of paraaortic/paracaval neurogenic tumors: surgical outcomes and technical tips. *Surg Endosc*. 2016; 30(10):4640-4645. [IF 3.1, CI 6]
145. Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K, Morioka K, Kishi R, **Shinohara N**, Takeda M, Nonomura K: The Relationship between the Second-to-Fourth Digit Ratio and Behavioral Sexual Dimorphism in School-Aged Children. *PloS one* 2016, 11(1):e0146849. [IF 3.7, CI 7]

146. Moriya K, Nakamura M, Nishimura Y, Kitta T, Kanno Y, Chiba H, Kon M, **Shinohara N**: Factors affecting post-pubertal penile size in patients with hypospadias. *World J Urol.* 2016, 34(9):1317-1321. [IF 3.4, CI 2]
147. Kon M, Saito K, Mitsui T, Miyado M, Igarashi M, Moriya K, Nonomura K, **Shinohara N**, Ogata T, Fukami M: Copy Number Variations of the Azoospermia Factor Region and SRY Are Not Associated with the Risk of Hypospadias. *Sex Dev.* 2016, 10(1):12-15. [IF 2.3, CI 2]
148. Kitta T, Mitsui T, Kanno Y, Chiba H, Moriya K, Yoshioka M, **Shinohara N**: Differences in neurotransmitter systems of ventrolateral periaqueductal gray between the micturition reflex and nociceptive regulation: An in vivo microdialysis study. *Int J Urol.* 2016, 23(7):593-598. [IF 2.6, CI 3]
149. Moriya K, Nakamura M, Nishimura Y, Kitta T, Kanno Y, Chiba H, Kon M, **Shinohara N**: Long-term impact of unilateral hypo/dysplastic kidney in infants with primary vesicoureteral reflux. *J Pediatr Urol.* 2016, pii: S1477-5131(16)00068-1. [IF 2.0, CI 0]
150. Itoh S, Araki A, Mitsui T, Miyashita C, Goudarzi H, Sasaki S, Cho K, Nakazawa H, Iwasaki Y, **Shinohara N**, Nonomura K, Kishi R: Association of perfluoroalkyl substances exposure in utero with reproductive hormone levels in cord blood in the Hokkaido Study on Environment and Children's Health. *Environ Int.* 2016, 94:51-59. [IF 11.8, CI 33]
151. Mitsui T, Araki A, Goudarzi H, Miyashita C, Ito S, Sasaki S, Kitta T, Moriya K, Cho K, Morioka K, Kishi R, **Shinohara N**, Takeda M, Nonomura K: Effects of adrenal androgens during the prenatal period on the second to fourth digit ratio in school-aged children. *Steroids* 2016, 113:46-51. [IF 2.7, CI 0]
152. Osawa T, Lee CT, Abe T, Takada N, Hafez KS, Montgomery JS, Weizer AZ, Hollenbeck BK, Skolarus TA, Murai S, **Shinohara N**, Morgan TM: A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy. *Bladder Cancer* 2016, 2(2):251-261. [IF 1.1, CI 7]
153. Kitta T, Yabe I, Takahashi I, Matsushima M, Sasaki H, **Shinohara N**: Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease. *Int J Urol.* 2016

Oct;23(10):893-894 [IF 2.6, CI 7]

154. Abe T, Matsumoto R, **Shinohara N**. Role of surgical consolidation in metastatic urothelial carcinoma. *Curr Opin Urol*. 2016 Nov;26(6):573-80. [IF 2.5, CI 6]
155. Nakamura A, Iwami D, Miyoshi H, Morita K, Taguri M, Terauchi Y, **Shinohara N**, Atsumi T: Impact of renal transplantation on glucose tolerance in Japanese recipients with impaired glucose tolerance. *Diabet Med*. 2017 Apr;34(4):569-576. [IF 3.5, CI 0]
156. Matsumoto R, Tsuda M, Yoshida K, Tanino M, Kimura T, Nishihara H, Abe T, **Shinohara N**, Nonomura K, Tanaka S: Aldo-keto reductase 1C1 induced by interleukin-1beta mediates the invasive potential and drug resistance of metastatic bladder cancer cells. *Sci Rep* 2016, 6:34625. [IF 4.6, CI 38]
157. Hida K, Maishi N, Kawamoto T, Akiyama K, Ohga N, Hida Y, Yamada K, Hojo T, Kikuchi H, Sato M, Torii C, **Shinohara N**, Shindoh M. Tumor endothelial cells express high pentraxin 3 levels. *Pathol Int*. 2016 Dec;66(12):687-694. [IF 2.2, CI 6]
158. Araki A, Mitsui T, Goudarzi H, Nakajima T, Miyashita C, Itoh S, Sasaki S, Cho K, Moriya K, **Shinohara N**, Nonomura K, Kishi R. Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The Hokkaido Study. *Sci Total Environ*. 2017 Mar1;581-582:297-304. [IF 9.8, CI 17]
159. Iwami D, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, **Shinohara N**: Highly Immunogenic DQB1 Mismatch Eplets Are Associated With Development of Chronic Active Antibody-Mediated Rejection: A First Report From Japan. *Transplant Proc* 2017, 49(1):84-87. [IF 0.9, CI 1]
160. Mitsui T, Morita K, Iwami D, Kitta T, Kanno Y, Moriya K, Takeda M, **Shinohara N**: Does the Age of Donor Kidneys Affect Nocturnal Polyuria in Patients With Successful Real Transplantation? *Transplant Proc* 2017, 49(1):65-67. [IF 0.9, CI 0]
161. Tomita Y, Fukasawa S, Oya M, Uemura H, **Shinohara N**, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, Naito S, Akaza H. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. *Jpn J Clin Oncol*. 2016 Nov 1;46(11):1031-1041.

[IF 2.4, CI 12]

162. Araki A, Miyashita C, Mitsui T, Goudarzi H, Mizutani F, Chisaki Y, Itoh S, Sasaki S, Cho K, Moriya K, **Shinohara N**, Nonomura K, Kishi R. Prenatal organochlorine pesticide exposure and the disruption of steroids and reproductive hormones in cord blood: The Hokkaido study. *Environ Int.* 2018 Jan;110:1-13. **[IF 11.8, CI 14]**
163. Tomita Y, Fukasawa S, **Shinohara N**, Kitamura H, Oya M, Eto M, Tanabe K, Kimura G, Yonese J, Yao M, Motzer RJ, Uemura H, McHenry MB, Berghorn E, Ozono S. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. *Jpn J Clin Oncol.* 2017 Jul 1;47(7):639-646. **[IF 2.4, CI 32]**
164. Takayanagi S, Mukasa A, Nakatomi H, Kanno H, Kuratsu JI, Nishikawa R, Mishima K, Natsume A, Wakabayashi T, Houkin K, Terasaka S, Yao M, **Shinohara N**, Shuin T, Saito N. Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan. *Neurol Med Chir (Tokyo).* 2017 Feb 15;57(2):59-65. **[IF 1.9, CI 2]**
165. Oya M, Tomita Y, Fukasawa S, **Shinohara N**, Habuchi T, Rini BI, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Uemura H. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study. *Cancer Sci.* 2017 Jun;108(6):1231-1239. **[IF 5.7, CI 9]**
166. Noguchi S, **Shinohara N**, Ito T, Ohtsu A, Ravaud A, Jerusalem G, Ohno N, Gallo J, Bouillaud E, Fan J, Nonomura N. Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials. *Oncology.* 2017;92(5):243-254. **[IF 3.5, CI 2]**
167. Nishioka K, Shimizu S, **Shinohara N**, Ito YM, Abe T, Maruyama S, Katoh N, Kinoshita R, Hashimoto T, Miyamoto N, Onimaru R, Shirato H. Analysis of inter- and intra fractional partial bladder wall movement using implanted fiducial markers. *Radiat Oncol.* 2017 Mar 1;12(1):44. **[IF 3.6, CI 3]**
168. Nishimura Y, Moriya K, Nakamura M, Nishida M, Sato M, Kudo Y, Omotehara S, Iwai T, Wakabayashi Y, Kanno Y, Kitta T, Kon M, **Shinohara N**. Prevalence and Chronological Changes of Testicular Microlithiasis in Isolated Congenital Undescended Testes Operated On at Less Than 3 Years of Age. *Urology.* 2017 Nov;109:159-164. **[IF 2.1,**

CI 2]

169. Moriya K, Nakamura M, Nishimura Y, Kanno Y, Kitta T, Kon M, **Shinohara N**. Prevalence of and risk factors for symptomatic urinary tract infection after endoscopic incision for the treatment of ureterocele in children. *BJU Int*. 2017 Sep;120(3):409-415. **[IF 4.5, CI 0]**
170. Minatoya M, Sasaki S, Araki A, Miyashita C, Itoh S, Yamamoto J, Matsumura T, Mitsui T, Moriya K, Cho K, Morioka K, Minakami H, Shinohara N, Kishi R. Cord Blood Bisphenol A Levels and Reproductive and Thyroid Hormone Levels of Neonates: The Hokkaido Study on Environment and Children's Health. *Epidemiology*. 2017 Oct;28 Suppl 1:S3-S9. **[IF 5.4, CI 16]**
171. Kitta T, Kanno Y, Chiba H, Moriya K, Maruyama S, Abe T, **Shinohara N**. Radical prostatectomy restores detrusor contraction pattern according to pressure flow parameters. *Int J Urol*. 2017 Apr;24(4):301-307. **[IF 2.6, CI 2]**
172. Hirose T, Tanaka Y, Tanaka A, Sakai H, Sasaki Y, **Shinohara N**, Ohdan H. PD-L1/PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice. *PLoS One*. 2017 Jun 1;12(6):e0178765. **[IF 3.7, CI 11]**
173. Hida K, Maishi N, Akiyama K, Ohmura-Kakutani H, Torii C, Ohga N, Osawa T, Kikuchi H, Morimoto H, Morimoto M, Shindoh M, **Shinohara N**, Hida Y. Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance. *Cancer Sci*. 2017 Nov;108(11):2195-2203. **[IF 5.7, CI 23]**
174. Hida K, Kawamoto T, Maishi N, Morimoto M, Akiyama K, Ohga N, Shindoh M, **Shinohara N**, Hida Y. miR-145 promoted anoikis resistance in tumor endothelial cells. *J Biochem*. 2017 Aug 1;162(2):81-84. **[IF 2.7, CI 4]**
175. Hara T, Fujimoto H, Kondo T, **Shinohara N**, Obara W, Kimura G, Kume H, Nonomura N, Hongo F, Sugiyama T, Kanayama HO, Takahashi M, Fukumori T, Eto M; Cancer Registration Committee of the Japanese Urological Association. Active heavy cigarette smoking is associated with poor survival in Japanese patients with advanced renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. *Jpn J Clin Oncol*. 2017 Dec 1;47(12):1162-1169. **[IF 2.4, CI 3]**

176. Araki A, Mitsui T, Goudarzi H, Nakajima T, Miyashita C, Itoh S, Sasaki S, Cho K, Moriya K, **Shinohara N**, Nonomura K, Kishi R. Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The Hokkaido Study. *Sci Total Environ*. 2017 Mar 1;581-582:297-304. [IF 9.8, CI 17]
177. Abe T, Takada N, Kikuchi H, Matsumoto R, Osawa T, Murai S, Miyajima N, Maruyama S, **Shinohara N**. Perioperative morbidity and mortality of octogenarians treated by radical cystectomy-a multi-institutional retrospective study in Japan. *Jpn J Clin Oncol*. 2017 Aug 1;47(8):755-761. [IF 2.4, CI 2]
178. Abe T, Ishizaki J, Kikuchi H, Minami K, Matsumoto R, Harabayashi T, Sazawa A, Mochizuki T, Chiba S, Akino T, Murakumo M, Miyajima N, Tsuchiya K, Maruyama S, Murai S, **Shinohara N**. Outcome of metastatic urothelial carcinoma treated by systemic chemotherapy: Prognostic factors based on real-world clinical practice in Japan. *Urol Oncol*. 2017 Feb;35(2):38.e1-38.e8. [IF 2.7, CI 10]
179. Takizawa A, Kawai K, Kawahara T, Kojima T, Maruyama S, **Shinohara N**, Akamatsu S, Kamba T, Nakamura T, Ukimura O, Jikuya R, Kishida T, Kakimoto K, Nishimura K, Harabayashi T, Nagamori S, Yamashita S, Arai Y, Sawada Y, Sekido N, Kinoshita H, Matsuda T, Nakagawa T, Homma Y, Nishiyama H. The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumor. *J Cancer Res Clin Oncol*. 2018 Jan;144(1):109-115. [IF 3.6, CI 2]
180. Ouchi M, Kitta T, Kanno Y, Moriya K, Suzuki S, **Shinohara N**, Kato K. Medium-term follow-up after supervised pelvic floor muscle training for patients with anterior vaginal wall prolapse. *Eur J Obstet Gynecol Reprod Biol*. 2018 Jun;225:95-100. [IF 2.6, CI 1]
181. Ouchi M, Kitta T, Kanno Y, Higuchi M, Togo M, Moriya K, **Shinohara N**. Effect of a 5-HT_{2c} receptor agonist on urethral closure mechanisms in female rats. *Neurourol Urodyn*. 2018 Nov;37(8):2382-2388. [IF 2.0, CI 0]
182. Osawa T, Abe T, Takada N, Ito YM, Murai S, **Shinohara N**. Validation of the nomogram for predicting 90-day mortality after radical cystectomy in a Japanese cohort. *Int J Urol*. 2018 Jul;25(7):699-700. [IF 2.6, CI 2]

183. Nakano K, Iwami D, Yamada T, Morita K, Yasuda K, Shibuya H, Kahata K, **Shinohara N**, Shimizu C. Development of a Formula to Correct Particle-Enhanced Turbidimetric Inhibition Immunoassay Values so That it More Precisely Reflects High-Performance Liquid Chromatography Values for Mycophenolic Acid. *Transplant Direct*. 2017 Dec 13;4(1):e337. [IF 2.3, CI 0]
184. Nakamura M, Moriya K, Nishimura Y, Nishida M, Kudo Y, Kanno Y, Kitta T, Kon M, **Shinohara N**. Prevalence and risk factors of testicular microlithiasis in patients with hypospadias: a retrospective study. *BMC Pediatr*. 2018 May 29;18(1):179. [IF 2.4, CI 3]
185. Moriya K, Nakamura M, Nishimura Y, Nishida M, Kudo Y, Kanno Y, Kitta T, Kon M, **Shinohara N**. Impact of Preoperative Ultrasonographic Evaluation for Detection of a Viable Testis in Patients With a Unilateral Nonpalpable Testis. *J Ultrasound Med*. 2018 Jul;37(7):1665-1670. [IF 2.3, CI 2]
186. Miyashita C, Araki A, Mitsui T, Itoh S, Goudarzi H, Sasaki S, Kajiwara J, Hori T, Cho K, Moriya K, **Shinohara N**, Nonomura K, Kishi R. Sex-related differences in the associations between maternal dioxin-like compounds and reproductive and steroid hormones in cord blood: The Hokkaido study. *Environ Int*. 2018 Aug;117:175-185.. [IF 11.8, CI 4]
187. Mitsui T, Araki A, Goudarzi H, Miyashita C, Ito S, Sasaki S, Kitta T, Moriya K, Cho K, Morioka K, Kishi R, **Shinohara N**, Takeda M, Nonomura K. Relationship between adrenal steroid hormones in cord blood and birth weight: The Sapporo Cohort, Hokkaido Study on Environment and Children's Health. *Am J Hum Biol*. 2018 Jul;30(4):e23127. [IF 2.9, CI 2]
188. Matsumoto R, Abe T, Ishizaki J, Kikuchi H, Harabayashi T, Minami K, Sazawa A, Mochizuki T, Akino T, Murakumo M, Osawa T, Maruyama S, Murai S, **Shinohara N**. Outcome and prognostic factors in metastatic urothelial carcinoma patients receiving second-line chemotherapy: an analysis of real-world clinical practice data in Japan. *Jpn J Clin Oncol*. 2018 Aug 1;48(8):771-776. [IF 2.4, CI 12]
189. Kon M, Mitsui T, Kitta T, Moriya K, **Shinohara N**, Takeda M, Nonomura K. Impact of posterior urethral diameter/external urethral sphincter diameter as a new tool to predict

- detrusor pressure in the voiding phase. *Int Urol Nephrol*. 2018 Feb;50(2):211-215. [IF 2.0, CI 0]
190. Kitta T, Yabe I, Kanno Y, Higuchi M, Ouchi M, Togo M, Moriya K, Takahashi I, Matsushima M, Sasaki H, **Shinohara N**. Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients. *Clin Neuropharmacol*. 2018 May/Jun;41(3):98-102. [IF 1.0, CI 7]
191. Kitta T, Kanno Y, Chiba H, Higuchi M, Ouchi M, Togo M, Moriya K, **Shinohara N**. Benefits and limitations of animal models in partial bladder outlet obstruction for translational research. *Int J Urol*. 2018 Jan;25(1):36-44. [IF 2.6, CI 18]
192. Iwami D, Aramaki O, **Shinohara N**, Niimi M, Shirasugi N. Administration of donor splenocytes via the respiratory tract generates CD8 α (+) regulatory dendritic cells and induces hyporesponsiveness to fully allogeneic cardiac grafts. *Transplant immunology*. 2018;50:60-7. [IF 1.5, CI 0]
193. Ito K, Mikami S, Tatsugami K, Masumori N, **Shinohara N**, Kondo T, Nakanishi S, Nagashima Y, Eto M, Kamba T, Kuroda N, Tomita Y, Matsuyama H, Onishi T, Tsushima T, Nakazawa H, Oya M, Ozono S, Naito S, Asano T. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan. *Clin Genitourin Cancer*. 2018 Dec;16(6):e1201-e1214.. [IF 3.2, CI 2]
194. Hirose T, Hotta K, Iwami D, Harada H, Morita K, Tanabe T, Sasaki H, Fukuzawa N, Seki T, **Shinohara N**. Safety and Efficacy of Retroperitoneoscopic Living Donor Nephrectomy: Comparison of Early Complication, Donor and Recipient Outcome with Hand-Assisted Laparoscopic Living Donor Nephrectomy. *J Endourol*. 2018 Dec;32(12):1120-1124.. [IF 2.7, CI 1]
195. Araki A, Miyashita C, Mitsui T, Goudarzi H, Mizutani F, Chisaki Y, Itoh S, Sasaki S, Cho K, Moriya K, **Shinohara N**, Nonomura K, Kishi R. Prenatal organochlorine pesticide exposure and the disruption of steroids and reproductive hormones in cord blood: The Hokkaido study. *Environ Int*. 2018 Jan;110:1-13.. [IF 11.8, CI 14]
196. Abe T, Raison N, **Shinohara N**, Shamim Khan M, Ahmed K, Dasgupta P. The Effect of Visual-Spatial Ability on the Learning of Robot-Assisted Surgical Skills. *Journal of*

surgical education. 2018;75(2):458-64. [IF 2.9, CI 6]

197. Abe T, Kondo T, Harabayashi T, Takada N, Matsumoto R, Osawa T, Minami K, Nagamori S, Maruyama S, Murai S, Tanabe K, **Shinohara N**. Comparative study of lymph node dissection, and oncological outcomes of laparoscopic and open radical nephroureterectomy for patients with urothelial carcinoma of the upper urinary tract undergoing regional lymph node dissection. *Jpn J Clin Oncol*. 2018 Nov 1;48(11):1001-1011.. [IF 2.4, CI 11]
198. Takahashi S, Kinuya S, Nonomura N, **Shinohara N**, Suzuki K, Suzuki H, Nakamura K, Satoh T, Tateishi U, Yoneda T, Horikoshi H, Igawa T, Kamai T, Koizumi M, Kosaka T, Matsubara N, Miyake H, Mizokami A, Mizowaki T, Nakamura N, Nozawa M, Takahashi T, Uemura H, Uemura M, Yokomizo A, Yoshimura M, Kakehi Y.: Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases. *Oncol Ther*. 2018 Dec;6(2):157-171. [IF 2.7, CI 1]
199. Tomita Y, Uemura H, Oya M, **Shinohara N**, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study. *BMC Cancer*. 2019 Jan 7;19(1):17.. [IF 3.8, CI 2]
200. Tomita Y, Fukasawa S, **Shinohara N**, Kitamura H, Oya M, Eto M, Tanabe K, Saito M, Kimura G, Yonese J, Yao M, Uemura H. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study. *Jpn J Clin Oncol*. 2019 Jun 1;49(6):506-514.. [IF 2.4, CI 28]
201. Tanaka N, Yamamoto M, Abe T, Osawa T, Matsumoto R, **Shinohara N**, Saito H, Uchida Y, Morimoto Y. Changes of Cerebral Blood Volume During Robot-Assisted Laparoscopic Radical Prostatectomy: Observational Prospective Study Using Near- Infrared Time-Resolved Spectroscopy. *J Endourol*. 2019 Dec;33(12):995-1001.. [IF 2.7, CI 8]
202. Sekizaki T, Kameda H, Oba C, Yong Cho K, Nakamura A, Miyoshi H, Osawa T, **Shinohara N**, Atsumi T. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. *Endocr J*. 2019 Oct 28;66(10):937-941.. [IF 2.0, CI 7]

203. Ouchi M, Kitta T, Suzuki S, **Shinohara N**, Kato K. Evaluating pelvic floor muscle contractility using two-dimensional transperineal ultrasonography in patients with pelvic organ prolapse. *Neurourology and urodynamics*. 2019;38(5):1363-9. **[IF 2.0, CI 3]**
204. Ouchi M, Kitta T, Kanno Y, Higuchi M, Togo M, Takahashi Y, Moriya K, **Shinohara N**. Dopaminergic urethral closure mechanisms in a rat model of Parkinson's disease. *Neurourol Urodyn*. 2019 Jun;38(5):1203-1211.. **[IF 2.0, CI 1]**
205. Osawa T, Wei JT, Abe T, Kako Y, Murai S, **Shinohara N**. Development of the Japanese version of the health-related quality of life questionnaire for bladder cancer patients using the Bladder Cancer Index: A pilot study. *Int J Urol*. 2019 Oct;26(10):1016-1017. **[IF 2.6, CI 2]**
206. Nishimura Y, Moriya K, Kobayashi S, Araki A, Sata F, Mitsui T, Itoh S, Miyashita C, Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, **Shinohara N**. Association between ESR1 polymorphisms and second to fourth digit ratio in school-aged children in the Hokkaido Study. *Steroids*. 2019 Jan;141:55-62. **[IF 2.7, CI 4]**
207. Moriya K, Nakamura M, Kon M, Nishimura Y, Kanno Y, Kitta T, **Shinohara N**. Risk factors affecting post-pubertal high serum follicle-stimulating hormone in patients with hypospadias. *World J Urol*. 2019 Dec;37(12):2795-2799.. **[IF 3.4, CI 1]**
208. Morii Y, Osawa T, Suzuki T, **Shinohara N**, Harabayashi T, Ishikawa T, Tanikawa T, Yamashina H, Ogasawara K. Cost comparison between open radical cystectomy, laparoscopic radical cystectomy, and robot-assisted radical cystectomy for patients with bladder cancer: a systematic review of segmental costs. *BMC Urol*. 2019 Nov 8;19(1):110.. **[IF 2.0, CI 10]**
209. Mitsui T, Araki A, Miyashita C, Ito S, Ikeno T, Sasaki S, Kitta T, Moriya K, Cho K, Morioka K, Kishi R, **Shinohara N**, Takeda M, Nonomura K. Effects of prenatal sex hormones on behavioral sexual dimorphism. *Pediatr Int*. 2019 Feb;61(2):140-146.. **[IF 1.4, CI 4]**
210. Mikami S, Mizuno R, Kondo T, **Shinohara N**, Nonomura N, Ozono S, Eto M, Tatsugami K, Takayama T, Matsuyama H, Kishida T, Oya M; Japanese Society of Renal Cancer. Clinical significance of programmed death-1 and programmed death- ligand 1

- expression in the tumor microenvironment of clear cell renal cell carcinoma. *Cancer Sci.* 2019 Jun;110(6):1820-1828.. [IF 5.7, CI 24]
211. Maishi N, Kikuchi H, Sato M, Nagao-Kitamoto H, Annan DA, Baba S, Hojo T, Yanagiya M, Ohba Y, Ishii G, Masutomi K, **Shinohara N**, Hida Y, Hida K. Development of Immortalized Human Tumor Endothelial Cells from Renal Cancer. *Int J Mol Sci.* 2019 Sep 17;20(18):4595.. [IF 5.6, CI 7]
212. Kume H, Homma Y, **Shinohara N**, Obara W, Kondo T, Kimura G, Fujimoto H, Nonomura N, Hongo F, Sugiyama T, Takahashi M, Kanayama HO, Fukumori T, Eto M. Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program. *Jpn J Clin Oncol.* 2019 Aug 1;49(8):772-779.. [IF 2.4, CI 2]
213. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, **Shinohara N**. Nephrometry score correlated with tumor proliferative activity in T1 clear cell renal cell carcinoma. *Urol Oncol.* 2019 May;37(5):301.e19-301.e25.. [IF 2.7, CI 9]
214. Iwami D, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, Iwahara N, **Shinohara N**. A 2-mm Cutoff Value Is Reasonable and Feasible for Vascular Reconstruction in a Kidney Allograft With Multiple Arteries. *Transplant Proc.* 2019 Jun;51(5):1317-1320.. [IF 0.9, CI 2]
215. Harada K, Nozawa M, Uemura M, Tatsugami K, Osawa T, Yamana K, Kimura G, Fujisawa M, Nonomura N, Eto M, **Shinohara N**, Tomita Y, Kondo Y, Ochi K, Anazawa Y, Uemura H. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. *Int J Urol.* 2019 Feb;26(2):202-210.. [IF 2.6, CI 14]
216. Dekura Y, Nishioka K, Hashimoto T, Miyamoto N, Suzuki R, Yoshimura T, Matsumoto R, Osawa T, Abe T, Ito YM, **Shinohara N**, Shirato H, Shimizu S. The urethral position may shift due to urethral catheter placement in the treatment planning for prostate radiation therapy. *Radiat Oncol.* 2019 Dec 12;14(1):226.. [IF 3.6, CI 9]
217. Annan DA, Maishi N, Soga T, Dawood R, Li C, Kikuchi H, Hojo T, Morimoto M, Kitamura T, Alam MT, Minowa K, **Shinohara N**, Nam JM, Hida Y, Hida K. Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment. *Cell Commun Signal.* 2019 Dec 17;17(1):169.. [IF 8.4, CI 24]

218. Abe T, Murai S, Nasuhara Y, **Shinohara N**. Characteristics of Medical Adverse Events/Near Misses Associated With Laparoscopic/Thoracoscopic Surgery: A Retrospective Study Based on the Japanese National Database of Medical Adverse Events. *J Patient Saf*. 2019 Dec;15(4):343-351.. [IF 2.2, CI 2]
219. Abe T, Dar F, Amnattrakul P, Aydin A, Raison N, **Shinohara N**, Khan MS, Ahmed K, Dasgupta P. The effect of repeated full immersion simulation training in ureterorenoscopy on mental workload of novice operators. *BMC Med Educ*. 2019 Aug 22;19(1):318.. [IF 3.6, CI 8]
220. Yokomizo A, Wakabayashi M, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S, Habuchi T, Kawashima K, Ishizuka O, **Shinohara N**, Sugimoto M, Yoshino Y, Nihei K, Fukuda H, Tobisu KI, Kakehi Y, Naito S; JCOG0401 Investigators. Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)[†]. *Eur Urol*. 2020 Jun;77(6):689-698.. [IF 23.4, CI 6]
221. Tomita Y, Naito S, Sassa N, Takahashi A, Kondo T, Koie T, Obara W, Kobayashi Y, Teishima J, Takahashi M, Matsuyama H, Ueda T, Yamaguchi K, Kishida T, Shiroki R, Saika T, **Shinohara N**, Oya M, Kanayama HO. Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC. *Clin Genitourin Cancer*. 2020 Aug;18(4):e374-e385.. [IF 3.2, CI 6]
222. Togo M, Kitta T, Kanno Y, Ouchi M, Tokiwa S, Huang T, Moriyama S, Nomura J, Moriya K, **Shinohara N**. Lower urinary tract function improves after laparoscopic sacrocolpopexy for elderly patients with pelvic organ prolapse. *Low Urin Tract Symptoms*. 2020 Sep;12(3):260-265.. [IF 1.3, CI 1]
223. Takada Y, Kamimura D, Jiang JJ, Higuchi H, Iwami D, Hotta K, Tanaka Y, Ota M, Higuchi M, Nishio S, Atsumi T, **Shinohara N**, Matsuno Y, Tsuji T, Tanabe T, Sasaki H, Iwahara N, Murakami M. Increased urinary exosomal SYT17 levels in chronic active antibody-mediated rejection after kidney transplantation via the IL-6 amplifier. *Int Immunol*. 2020 Sep 30;32(10):653-662.. [IF 4.4, CI 11]
224. Ouchi M, Kitta T, Takahashi Y, Chiba H, Higuchi M, Togo M, **Shinohara N**.

- Reliability of manometry for assessing pelvic floor muscle function in healthy men. *Neurourol Urodyn.* 2020 Jun;39(5):1464-1471.. [IF 2.0, CI 2]
225. Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Tamura K, Komiyama M, Goto T, Yokomizo A, Kohei N, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Iwamoto H, Mitsuzuka K, Morooka D, Shimazui T, Yamamoto Y, Ikeshiro S, Nakagomi H, Morita K, Tomida R, Mochizuki T, Inoue T, Kitamura H, Yamada S, Ito YM, Murai S, Nishiyama H, **Shinohara N**; Japanese Urological Oncology Group. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. *Cancer Sci.* 2020 Jul;111(7):2460-2471.. [IF 5.7, CI 0]
226. Nishimura Y, Moriya K, Kobayashi S, Araki A, Sata F, Mitsui T, Itoh S, Miyashita C, Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, **Shinohara N**. Association of exposure to prenatal phthalate esters and bisphenol A and polymorphisms in the ESR1 gene with the second to fourth digit ratio in school- aged children: Data from the Hokkaido study. *Steroids.* 2020 Jul;159:108637.. [IF 2.7, CI 6]
227. Miyata H, Osawa T, Abe T, Kikuchi H, Matsumoto R, Maruyama S, Nishioka K, Shimizu S, Hashimoto T, Shirato H, **Shinohara N**. The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer. *Jpn J Clin Oncol.* 2020 May 5;50(5):609-616.. [IF 2.4, CI 0]
228. Mitsui T, Araki A, Miyashita C, Ito S, Kitta T, Moriya K, **Shinohara N**, Takeda M, Kishi R; Japan Environment and Children's Study Group*. Effect of the occupational environment of parents on cryptorchidism. *Pediatr Int.* 2020 Nov;62(11):1256-1263.. [IF 1.4, CI 1]
229. Matsumoto R, Abe T, Takada N, Minami K, Harabayashi T, Nagamori S, Hatanaka KC, Yamashiro K, Kikuchi H, Osawa T, Maruyama S, **Shinohara N**. Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up study. *Urol Oncol.* 2020 Dec;38(12):933.e13-933.e18.. [IF 2.7, CI 3]
230. Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa

- O, Kikuchi E, Kitamura H, **Shinohara N**, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper. *Int J Urol*. 2020 May;27(5):362-368.. [IF 2.6, CI 7]
231. Higuchi H, Kamimura D, Jiang JJ, Atsumi T, Iwami D, Hotta K, Harada H, Takada Y, Kanno-Okada H, Hatanaka KC, Tanaka Y, **Shinohara N**, Murakami M. Orosomucoid 1 is involved in the development of chronic allograft rejection after kidney transplantation. *Int Immunol*. 2020 May 8;32(5):335-346. [IF 4.4, CI 10]
232. Chiba H, Kitta T, Ohmura Y, Higuchi M, Kon M, Nakamura M, Yoshioka M, **Shinohara N**. Serotonin in the rat prefrontal cortex controls the micturition reflex through 5-hydroxytryptamine 2A and 5-hydroxytryptamine 7 receptors. *Int J Urol*. 2020 Aug;27(8):684-689.. [IF 2.6, CI 3]
233. Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, Miyata H, Frumido J, Matsumoto R, Osawa T, Junji I, Tango M, Satoshi C, Tomoshige A, Masashi M, Naoto M, Kunihiko T, Satoru M, Murai S, **Shinohara N**. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. *Jpn J Clin Oncol*. 2020 Feb 17;50(2):206-213.. [IF 2.4, CI 6]
234. Kikuchi H, Maishi N, Annan DA, Alam MT, Dawood RIH, Sato M, Morimoto M, Takeda R, Ishizuka K, Matsumoto R, Akino T, Tsuchiya K, Abe T, Osawa T, Miyajima N, Maruyama S, Harabayashi T, Azuma M, Yamashiro K, Ameda K, Kashiwagi A, Matsuno Y, Hida Y, **Shinohara N**, Hida K. Chemotherapy-Induced IL8 Upregulates MDR1/ABCB1 in Tumor Blood Vessels and Results in Unfavorable Outcome. *Cancer Res*. 2020 Jul 15;80(14):2996-3008.. [IF 11.2, CI 13]
235. Matsumoto H, Shiraishi K, Azuma H, Inoue K, Uemura H, Eto M, Ohyama C, Ogawa O, Kikuchi E, Kitamura H, **Shinohara N**, Takahashi S, Tsuzuki T, Nakagawa M, Narumi Y, Nishiyama H, Habuchi T, Hinotsu S, Fujii Y, Fujimoto K, Fujimoto H, Mizowaki T, Matsuyama H. Clinical Practice Guidelines for Bladder Cancer 2019 update by the Japanese Urological Association: Summary of the revision. *Int J Urol*. 2020 Sep;27(9):702-709.. [IF 2.6, CI 23]

236. Kitta T, Chiba H, Kanno Y, Hattori T, Higuchi M, Ouchi M, Togo M, Takahashi Y, Michishita M, Kitano T, **Shinohara N**. Bladder outlet obstruction disrupts circadian bladder function in mice. *Sci Rep*. 2020 Jul 14;10(1):11578. [IF 4.6, CI 2]
237. Higuchi M, Abe T, Hotta K, Morita K, Miyata H, Furumido J, Iwahara N, Kon M, Osawa T, Matsumoto R, Kikuchi H, Kurashima Y, Murai S, Aydin A, Raison N, Ahmed K, Khan MS, Dasgupta P, **Shinohara N**. Development and validation of a porcine organ model for training in essential laparoscopic surgical skills. *Int J Urol*. 2020 Oct;27(10):929-938. [IF 2.6, CI 4]
238. Tohi Y, Kato T, Matsumoto R, **Shinohara N**, Shiga K, Yokomizo A, Nakamura M, Kume H, Mitsuzuka K, Sasaki H, Egawa S, Matsumura M, Hashine K, Inokuchi J, Eto M, Baba H, Ichikawa T, Kinoshita H, Matsuda T, Kakehi Y, Sugimoto M. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study. *Int J Clin Oncol*. 2020 Dec;25(12):2107-2114 [IF 3.3, CI 4]
239. Osawa T, Wei JT, Abe T, Honda M, Yamada S, Furumido J, Kikuchi H, Matsumoto R, Hirakawa K, Sato Y, Sasaki Y, Harabayashi T, Takada N, Minami K, Tanaka H, Morita K, Kashiwagi A, Miyajima N, Akino T, Murai S, Ito YM, Fukuhara S, Ogasawara K, **Shinohara N**. Health-related quality of life in Japanese patients with bladder cancer measured by a newly developed Japanese version of the Bladder Cancer Index. *Int J Clin Oncol*. 2020 Dec;25(12):2090-2098. [IF 3.3, CI 2]
240. Ebina K, Abe T, Higuchi M, Furumido J, Iwahara N, Kon M, Hotta K, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, **Shinohara N**. Motion analysis for better understanding of psychomotor skills in laparoscopy: objective assessment-based simulation training using animal organs. *Surg Endosc*. 2021 Aug;35(8):4399-4416. [IF 3.1, CI 9]
241. Kitta T, Chiba H, Kanno-Kakibuchi Y, Hattori T, Higuchi M, Ouchi M, Togo M, Abe-Takahashi Y, Michishita M, Kitano T, **Shinohara N**. Long-term administration of alpha-1 blocker can reverse the micturition pattern in a bladder outlet obstruction murine model. *Int J Urol*. 2020 Dec;27(12):1150-1156. [IF 2.6, CI 0]

242. Yoshinaga K, Abe T, Okamoto S, Uchiyama Y, Manabe O, Ito YM, Tamura N, Ito N, Yoshioka N, Washino K, **Shinohara N**, Tamaki N, Shiga T. Effects of Repeated ¹³¹I-*Meta*-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors. *J Nucl Med*. 2021 May 10;62(5):685-694. [IF 9.3, CI 1]
243. Ito K, Mikami S, Kuroda N, Nagashima Y, Tatsugami K, Masumori N, Kondo T, Takagi T, Nakanishi S, Eto M, Kamba T, Tomita Y, Matsuyama H, Tsushima T, Nakazawa H, Oya M, Kimura G, **Shinohara N**, Asano T. Difficulty in differential diagnosis for renal cancer with microscopic papillary architecture: overlapped pathological features among papillary renal cell carcinoma (RCC), mutinous tubular and spindle cell carcinoma, and unclassified RCC. Lessons from a Japanese multicenter study *Jpn J Clin Oncol*. 2020 Oct 22;50(11):1313-1320. [IF 2.4, CI 0]
244. Yamashita S, Suzukamo Y, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, **Shinohara N**, Ito A, Arai Y. Validation study of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Testicular Cancer 26 for patients with testicular cancer. *Int J Urol*. 2021 Feb;28(2):176-182. [IF 2.6, CI 2]
245. Abe-Takahashi Y, Kitta T, Ouchi M, Okayauchi M, Chiba H, Higuchi M, Togo M, **Shinohara N**. Reliability and validity of pelvic floor muscle strength assessment using the MizCure perineometer. *BMC Womens Health*. 2020 Nov 19;20(1):257. [IF 2.5, CI 2]
246. Kitta T, Hattori T, Chiba H, Higuchi M, Kanno-Kakibuchi Y, Ouchi M, Togo M, Abe-Takahashi Y, Michishita M, Kitano T, Kusakabe N, **Shinohara N**. Are sham- operated mice a valid comparator in studies using a bladder outlet obstruction model? A pitfall reveals a meaningful insight. *Int J Urol*. 2021 Mar;28(3):346-352. [IF 2.6, CI 0]
247. Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, **Shinohara N**; Japanese Urological Oncology Group. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. *J Geriatr Oncol*. 2021 Jun;12(5):834-837. [IF 3.0, CI 0]

248. Nakamura M, Moriya K, Kon M, Nishimura Y, Chiba H, Kitta T, **Shinohara N**. Girls and renal scarring as risk factors for febrile urinary tract infection after stopping antibiotic prophylaxis in children with vesicoureteral reflux. *World J Urol*. 2021 Jul;39(7):2587-2595. **[IF 3.4, CI 2]**
249. Tamura K, Osawa T, Takeuchi A, Minami K, Nakai Y, Ueda K, Ozawa M, Uemura M, Sugimoto M, Ohba K, Suzuki T, Anai S, Shindo T, Kusakabe N, Komiyama M, Tanaka K, Yokomizo A, Kohei N, **Shinohara N**, Miyake H; Japanese Urological Oncology Group. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. *Jpn J Clin Oncol*. 2021 Apr 30;51(5):810-818. **[IF 2.4, CI 0]**
250. Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, **Shinohara N**. Examination of pelvic floor muscle elasticity in patients with interstitial cystitis/bladder pain syndrome using real-time tissue elastography. *Int Urogynecol J*. 2022 Mar;33(3):619-626. **[IF 1.8, CI 0]**
251. Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, **Shinohara N**, Suzukamo Y, Ito A, Arai Y. Health-Related Quality of Life in Testicular Cancer Survivors in Japan: A Multi-Institutional, Cross-Sectional Study Using the EORTC QLQ-TC26. *Urology*. 2021 Oct;156:173-180. **[IF 2.1, CI 2]**
252. Tanabe T, Hotta K, Iwahara N, Iwami D, Murai S, **Shinohara N**. Spontaneous closure of arteriovenous fistula after kidney transplantation. *Int J Urol*. 2021 Aug;28(8):872-873. **[IF 2.6, CI 0]**
253. Miyake M, Nishimura N, Iida K, Fujii T, Nishikawa R, Teraoka S, Takenaka A, Kikuchi H, Abe T, **Shinohara N**, Okajima E, Shimizu T, Hori S, Tsuchiya N, Owari T, Murakami Y, Taoka R, Kobayashi T, Kojima T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies. *Cancers (Basel)*. 2021 May 26;13(11):2615. **[IF 5.2, CI 4]**

254. Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Yamada S, Nishimura K, Nonomura N, Kojo K, Shiraishi T, Ukimura O, Ogawa O, **Shinohara N**, Suzukamo Y, Ito A, Arai Y. Fertility and reproductive technology use in testicular cancer survivors in Japan: A multi-institutional, cross-sectional study. *Int J Urol*. 2021 Oct;28(10):1047-1052. [IF 2.6, CI 4]
255. Uemura M, Nakaigawa N, Sassa N, Tatsugami K, Harada K, Yamasaki T, Matsubara N, Yoshimoto T, Nakagawa Y, Fukuyama T, Oya M, **Shinohara N**, Uemura H, Tsuzuki T. Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma. *Int J Clin Oncol*. 2021 Nov;26(11):2073-2084. [IF 3.3, CI 2]
256. Togo M, Kitta T, Chiba H, Ouchi M, Abe-Takahashi Y, Higuchi M, Kusakabe N, **Shinohara N**. Can ultrasound measurement of bladder wall thickness be a useful adjunct for regular urodynamics in children with spina bifida? *J Pediatr Urol*. 2021 Oct;17(5):734.e1-734.e8. [IF 2.0, CI 0]
257. Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, **Shinohara N**, Torigoe T. GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy. *Cancer Immunol Immunother*. 2022 Apr;71(4):795-806. [IF 5.8, CI 3]
258. Kobayashi S, Sata F, Ikeda-Araki A, Miyashita C, Itoh S, Goudarzi H, Iwasaki Y, Mitsui T, Moriya K, **Shinohara N**, Cho K, Kishi R. Associations among maternal perfluoroalkyl substance levels, fetal sex-hormone enzymatic gene polymorphisms, and fetal sex hormone levels in the Hokkaido study. *Reprod Toxicol*. 2021 Oct;105:221-231. [IF 3.3, CI 1]
259. Kikuchi H, Osawa T, Matsumoto R, Abe T, Maruyama S, Harabayashi T, Miyata H, Kashiwagi A, Ikeshiro S, Sazawa A, Fukui R, Morita K, Takeuchi I, Hori K, Yamashita N, Minami K, Mochizuki T, Murai S, **Shinohara N**. Efficacy of nivolumab plus ipilimumab as first-line therapy for primary tumors in patients with renal cell carcinoma. *Urol Oncol*. 2022 Jan;40(1):13.e19-13.e27. [IF 2.7, CI 0]
260. Yamada S, Abe T, Sazawa A, Katano H, Suzuki H, Takeuchi I, Ishizaki J, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Ishikawa S, Sato S, Kawazu T, Yamashita T, Ono T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Furumido J, Miyata H, Kikuchi H, Matsumoto

- R, Osawa T, **Shinohara N**. Comparative study of postoperative complications after radical cystectomy during the past two decades in Japan: Radical cystectomy remains associated with significant postoperative morbidities. *Urol Oncol*. 2022 Jan;40(1):11.e17-11.e25. [IF 2.7, CI 2]
261. Kon M, Nakamura M, Moriya K, Nishimura Y, Hirata Y, Nishida M, Higuchi M, Kitta T, **Shinohara N**. What are the Optimal Renal Ultrasound Parameters for Detecting Small Kidney in Young Children? *Res Rep Urol*. 2021 Oct 27;13:767-772. [IF 1.6, CI 1]
262. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, **Shinohara N**, Aoyama H, Shimizu S, Shirato H. Are simple verbal instructions sufficient to ensure that bladder volume does not deteriorate prostate position reproducibility during spot scanning proton therapy? *BJR Open*. 2021 Nov 11;3(1):20210064. [IF NA, CI 0]
263. Aydın A, Ahmed K, Abe T, Raison N, Van Hemelrijck M, Garmo H, Ahmed HU, Mukhtar F, Al-Jabir A, Brunckhorst O, **Shinohara N**, Zhu W, Zeng G, Sfakianos JP, Gupta M, Tewari A, Gözen AS, Rassweiler J, Skolarikos A, Kunit T, Knoll T, Moltzahn F, Thalmann GN, Lantz Powers AG, Chew BH, Sarica K, Shamim Khan M, Dasgupta P; SIMULATE Trial Group. Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial. *Eur Urol*. 2022 Apr;81(4):385-393. [IF 23.4, CI 13]
264. Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S, **Shinohara N**. Outcomes of bacillus Calmette-Guérin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era. *Int J Urol*. 2022 Mar;29(3):251-258. [IF 2.6, CI 1]
265. Nakajima N, Miyajima A, **Shinohara N**, Obara W, Kondo T, Kimura G, Kume H, Fujimoto H, Sugiyama T, Nonomura N, Hongo F, Fukumori T, Takahashi M, Kanayama HO, Eto M. Risk factors for recurrence after operation in patients with pT1a renal cell carcinoma: sub-analysis of the multi-institutional national database of the Japanese Urological Association. *Jpn J Clin Oncol*. 2022 Mar 3;52(3):274-280. [IF 2.4, CI 0]
266. Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T,

- Okada H, Kawai K, **Shinohara N**, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. *Int J Clin Oncol*. 2022 Feb;27(2):265-280. [IF 3.3, CI 6]
267. Harada M, Kimura F, Takai Y, Nakajima T, Ushijima K, Kobayashi H, Satoh T, Tozawa A, Sugimoto K, Saji S, Shimizu C, Akiyama K, Bando H, Kuwahara A, Furui T, Okada H, Kawai K, **Shinohara N**, Nagao K, Kitajima M, Suenobu S, Soejima T, Miyachi M, Miyoshi Y, Yoneda A, Horie A, Ishida Y, Usui N, Kanda Y, Fujii N, Endo M, Nakayama R, Hoshi M, Yonemoto T, Kiyotani C, Okita N, Baba E, Muto M, Kikuchi I, Morishige KI, Tsugawa K, Nishiyama H, Hosoi H, Tanimoto M, Kawai A, Sugiyama K, Boku N, Yonemura M, Hayashi N, Aoki D, Osuga Y, Suzuki N. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. *Int J Clin Oncol*. 2022 Feb;27(2):265-280. [IF 3.3, CI 7]
268. Nishimura Y, Moriya K, Kobayashi S, Ikeda-Araki A, Sata F, Mitsui T, Itoh S, Miyashita C, Cho K, Kon M, Nakamura M, Kitta T, Murai S, Kishi R, **Shinohara N**. Association of exposure to prenatal perfluoroalkyl substances and estrogen receptor 1 polymorphisms with the second to fourth digit ratio in school-aged children: The Hokkaido study. *Reprod Toxicol*. 2022 Apr;109:10-18. [IF 3.3, CI 0]
269. Osawa T, Abe T, Kikuchi H, Matsumoto R, Murai S, Nakao T, Tanaka S, Watanabe, **Shinohara N**. Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms. *PLoS One*. 2022 Mar 15;17(3):e0265230. [IF 3.7, CI 0]
270. Ouchi M, Kitta T, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, **Shinohara N**. Mechanisms of D1/D2-like dopaminergic agonist, rotigotine, on lower urinary tract function in rat model of Parkinson's disease. *Sci Rep*. 2022 Mar 16;12(1):4540.. [IF 4.6, CI 0]
271. Hirose T, Hotta K, Harada H, Tanabe T, Sasaki H, **Shinohara N**. Vesicoureteral reflux treatment following kidney transplantation potentially prevents graft function deterioration and allows long-term graft survival. *Int J Urol*. 2022 Jul;29(7):699-706. [IF 2.6, CI 0]

272. Chiba H, Kitta T, Higuchi M, Kusakabe N, Kon M, Nakamura M, **Shinohara N**. Ureteral reimplantation during augmentation cystoplasty is not needed for vesicoureteral reflux in patients with neurogenic bladder: a long-term retrospective study. *BMC Urol*. 2022 Mar 29;22(1):48. **[IF 2.0, CI 2]**
273. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, **Shinohara N**. Objective evaluation of laparoscopic surgical skills in wet lab training based on motion analysis and machine learning. *Langenbecks Arch Surg*. 2022 Aug;407(5):2123-2132. **[IF 2.3, CI 2]**
274. Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, **Shinohara N**. Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance. *Int J Clin Oncol*. 2022 Jun;27(6):1061-1067. **[IF 3.3, CI 0]**
275. Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, Miura K, Sakamoto N, **Shinohara N**, Yamashita S, Yonemori K, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. *Int J Urol*. 2022 Jul;29(7):741-747. **[IF 2.6, CI 1]**
276. Kitta T, Abe H, Ting-Wen H, Fujikawa M, Nakazono M, Sasa T, Doi Y, Toki S, Okada D, Ochi A, Suzuki K, Kitagawa Y, **Shinohara N**. Novel insight into the correlation between hernia orifice of cystocele and lower urinary tract function: a pilot study. *BMC Womens Health*. 2022 May 13;22(1):164. **[IF 2.5, CI 0]**
277. Hirata Y, Higuchi M, Osawa T, Hinotsu S, Harabayashi T, Mochizuki T, Enami N, Nounaka O, Shinno Y, Kikuchi H, Matsumoto R, Abe T, Murai S, **Shinohara N**. Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods. *Int J Urol*. 2022 Oct;29(10):1140-1146. **[IF 2.6, CI 0]**
278. Nishioka K, Gotoh K, Hashimoto T, Abe T, Osawa T, Matsumoto R, Yokota I, Katoh N, Kinoshita R, Yasuda K, Yakabe T, Yoshimura T, Takao S, **Shinohara N**, Aoyama H, Shimizu S, Shirato H. Are simple verbal instructions sufficient to ensure that bladder volume

does not deteriorate prostate position reproducibility during spot scanning proton therapy?
BJR Open. 2021 Nov 11;3(1):20210064. [IF NA, CI 0]

279. Abe-Takahashi Y, Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, **Shinohara N**. Evaluation of pelvic floor muscle elasticity in patients with overactive bladder syndrome using real-time tissue elastography. *Eur J Obstet Gynecol Reprod Biol*. 2022 Sep;276:9-13. [IF 2.6, CI 0]
280. Yamamoto S, Noguchi H, Takeda A, Arakaki R, Uchishiba M, Imaizumi J, Minato S, Kamada S, Kagawa T, Yoshida A, Kawakita T, Yamamoto Y, Yoshida K, Kon M, **Shinohara N**, Iwasa T. Changes in Endogenous Oxytocin Levels and the Effects of Exogenous Oxytocin Administration on Body Weight Changes and Food Intake in Polycystic Ovary Syndrome Model Rats. *Int J Mol Sci*. 2022 Jul 26;23(15):8207. [IF 5.6, CI 3]
281. Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, Togo M, Abe- Takahashi Y, Tsukiyama M, **Shinohara N**. Urodynamic evaluation of the efficacy of vibegron, a new β 3-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. *J Pediatr Urol*. 2022 Oct;18(5):563-569. [IF 2.0, CI 0]
282. Yamada R, Morikawa K, Hotta K, Iwami D, Tanabe T, Murai S, **Shinohara N**, Yoshida S, Hosoda S, Kubo A, Tokuchi Y, Kitagataya T, Kimura M, Yamamoto K, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Incidence of post- transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. *J Viral Hepat*. 2022 Nov;29(11):976-985. [IF 2.5, CI 1]
283. Nezu K, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Negoro H, Shiraishi T, Ukimura O, Ogawa O, **Shinohara N**, Suzukamo Y, Ito A, Arai Y. Association of financial toxicity with quality of life in testicular cancer survivors. *Int J Urol*. 2022 Dec;29(12):1526-1534. [IF 2.6, CI 0]
284. Furumido J, Maishi N, Yanagawa-Matsuda A, Kikuchi H, Matsumoto R, Osawa T, Abe T, Matsuno Y, **Shinohara N**, Hida Y, Hida K. Stroma biglycan expression can be a prognostic factor in prostate cancers. *Int J Urol*. 2023 Feb;30(2):147-154. [IF 2.6, CI 1]
285. Kikuchi H, Osawa T, Abe T, Matsumoto R, Maruyama S, Murai S, **Shinohara N**. Quality improvement in managing patients with non-muscle-invasive bladder cancer by

- introducing a surgical checklist for transurethral resection of bladder tumor. *PLoS One*. 2022 Oct 27;17(10):e0276816. [IF 3.7, CI 0]
286. Takenaka J, Watanabe S, Abe T, Hirata K, Uchiyama Y, Kimura R, **Shinohara N**, Kudo K. Prognostic value of [¹⁸F]FDG-PET prior to [¹³¹I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL). *Ann Nucl Med*. 2023 Jan;37(1):10-1. [IF 2.6, CI 2]
287. Ebina K, Abe T, Hotta K, Higuchi M, Furumido J, Iwahara N, Kon M, Miyaji K, Shibuya S, Lingbo Y, Komizunai S, Kurashima Y, Kikuchi H, Matsumoto R, Osawa T, Murai S, Tsujita T, Sase K, Chen X, Konno A, **Shinohara N**. Automatic assessment of laparoscopic surgical skill competence based on motion metrics. *PLoS One*. 2022 Nov 2;17(11):e0277105. [IF 3.7, CI 0]
288. Iwasa T, Noguchi H, Aoki H, Tamura K, Maeda T, Takeda A, Uchishiba M, Arakaki R, Minato S, Kamada S, Yamamoto S, Imaizumi J, Kagawa T, Yoshida A, Fukui R, Daizumoto K, Kon M, **Shinohara N**, Yoshida K, Yamamoto Y. Effects of undernutrition and low energy availability on reproductive functions and their underlying neuroendocrine mechanisms. *Endocr J*. 2022 Dec 28;69(12):1363-1372. [IF 2.0, CI 2]
289. Sato M, Osawa T, Abe T, Honda M, Higuchi M, Yamada S, Furumido J, Kikuchi H, Matsumoto R, Sato Y, Sasaki Y, Harabayashi T, Maruyama S, Takada N, Minami K, Tanaka H, Morita K, Kashiwagi A, Murai S, Ito YM, Ogasawara K, **Shinohara N**. Validation of the Japanese version of the Body Image Scale for bladder cancer patients. *Sci Rep*. 2022 Dec 13;12(1):21544. [IF 4.6, CI 0]
290. Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, **Shinohara N**, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. *BMC Cancer*. 2022 Dec 9;22(1):1292. [IF 3.8, CI 0]
291. Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, **Shinohara N**, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu

- S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNiP-RCC investigators. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial. *Cancer Immunol Immunother.* 2023 Jun;72(6):1903-1915. [IF 5.8, CI 1]
292. Sakka S, Kandori S, Kawai K, Kojima T, Nitta S, Chihara I, Nagumo Y, Kawahara T, Mathis BJ, Ishihara M, **Shinohara N**, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Plasma circulating tumor DNA profiling in patients with chemo-refractory germ cell tumors. *Int J Urol.* 2023 May;30(5):456-462. [IF 2.6, CI 0]
293. Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, **Shinohara N**, Hirohashi Y, Torigoe T. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma. *Cancer Immunol Immunother.* 2023 Jul;72(7):2057-2065. [IF 5.8, CI 0]
294. Yamamoto S, Arakaki R, Noguchi H, Takeda A, Uchishiba M, Kamada S, Mineda A, Kon M, Kawakita T, Kinouchi R, Yamamoto Y, Yoshida K, **Shinohara N**, Iwasa T. New discoveries on the interaction between testosterone and oxytocin in male rats - Testosterone-mediated effects of oxytocin in the prevention of obesity. *Physiol Behav.* 2023 Jul 1;266:114199. [IF 2.9, CI 0]
295. Iwahara N, Hotta K, Hirose T, **Shinohara N**. Long-Term Results in Recipients of Late Conversion to a Calcineurin Inhibitor-Free Regimen with Everolimus After Kidney Transplantation. *Transplant Proc.* 2023 May;55(4):803-808. [IF 0.9, CI 0]
296. Uemura H, **Shinohara N**, Tomita Y, Nonomura N, Yamada T, Yoshida A, Komoto A. The safety profile of nivolumab plus ipilimumab combination therapy in Japanese patients with renal cell carcinoma: results from post-marketing surveillance. *Jpn J Clin Oncol.* 2023 Jul 31;53(8):730-737. [IF 2.4, CI 0]
297. Iwahara N, Hotta K, Iwami D, Tanabe T, Tanaka Y, Ito YM, Otsuka T, Murai S, Takada Y, Higuchi H, Sasaki H, Hirose T, Harada H, **Shinohara N**. Analysis of T-cell alloantigen response *via* a direct pathway in kidney transplant recipients with donor-specific antibodies. *Front Immunol.* 2023 May 3;14:1164794. [IF 7.3, CI 0]

298. Abe T, Yamada S, Kikuchi H, Sazawa A, Katano H, Suzuki H, Takeuchi I, Minami K, Morita K, Tsuchiya K, Takada N, Maru S, Sato S, Yamashita T, Mochizuki T, Akino T, Sasaki Y, Shinno Y, Murahashi N, Kawazu T, Furumido J, Miyata H, Matsumoto R, Osawa T, Murai S, **Shinohara N**. Impact of postoperative complications on long-term survival in bladder cancer patients. *Jpn J Clin Oncol*. 2023 Oct 4;53(10):966-976. [IF 2.4, CI 0]
299. Osawa T, Fujii Y, Kimura G, Kitamura H, Nagashima Y, Iizumi S, Osaka T, Tsubouchi R, **Shinohara N**. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). *BMJ Open*. 2023 Jul 26;13(7):e070275. [IF 2.9, CI 0]
300. Blas L, Shiota M, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, **Shinohara N**, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tanegashima T, Tokunaga S, Eto M; SNIp-RCC Investigators. Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNIp-RCC study. *Int J Urol*. 2023 Sep;30(9):788-796. [IF 2.6, CI 0]
301. Koyama J, Yamashita S, Kakimoto K, Uemura M, Kishida T, Kawai K, Nakamura T, Goto T, Osawa T, Nishimura K, Nonomura N, Nishiyama H, Shiraishi T, Ukimura O, Ogawa O, **Shinohara N**, Suzukamo Y, Ito A, Arai Y. Sexual function using the EORTC QLQ-TC26 in testicular cancer survivors: A multi-institutional, cross-sectional study. *Int J Urol*. 2023 Nov;30(11):1044-1050. [IF 2.6, CI 0]
302. Yagi Y, Kubo Y, Hoshino K, Okada K, Hotta K, **Shinohara N**, Morimoto Y. Differences of cerebral oxygen saturation in dialysis patients: a comparison of three principals of near infrared spectroscopy. *J Anesth*. 2023 Dec;37(6):861-867. [IF 2.8, CI 0]
303. Kato T, Wang C, Masumori N, Yamasaki T, Matsumoto H, Baba M, Ito K, Kimura T, Kitamura H, Takahashi M, Hongo F, Hasine K, Eto M, Ikeda JI, Nonomura N, **Shinohara N**. T1a Renal Cell Carcinoma With Metastasis: Japanese Society of Renal Cancer Retrospective Multi-institute Results. *Anticancer Res*. 2023 Sep;43(9):4061-4065. [IF 2.0, CI 0]
304. Kusakabe N, Kamijo TC, Wada N, Chiba H, **Shinohara N**, Miyazato M. Effects of low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat

model of interstitial cystitis/bladder pain syndrome. *Int Urol Nephrol*. 2024 Jan;56(1):77-86. [IF 2.0, CI 0]

305. Togo M, Kitta T, Chiba H, Higuchi M, Kusakabe N, Ouchi M, Abe-Takahashi Y, Kakizaki H, **Shinohara N**. Effects of a new selective β_3 -adrenoceptor agonist, vibegron, on bladder and urethral function in a rat model of Parkinson's disease. *Low Urin Tract Symptoms*. 2023 Nov;15(6):265-270. [IF 1.3, CI 0]
306. Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, **Shinohara N**, Kitamura H; Japanese Urological Oncology Group. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment. *Urol Oncol*. 2023 Nov;41(11):458.e9-458.e19. [IF 2.7, CI 0]
307. Takenaka J, Watanabe S, Abe T, Tsuchikawa T, Takeuchi S, Hirata K, Kimura R, Wakabayashi N, **Shinohara N**, Kudo K. Predictive factors of early FDG-PET response to [131I] MIBG treatment for unresectable or metastatic pheochromocytomas and paragangliomas (PPGLs). *Neuroendocrinology*. 2023 Sep 19. doi: 10.1159/000534175. [IF 4.1, CI 0]
308. Kitta T, Kanno-Kakibuchi Y, Chiba H, Higuchi M, Ouchi M, Togo M, Abe-Takahashi Y, Tsukiyama M, **Shinohara N**. Episodes of Febrile Urinary Tract Infections Occur More Often in the Winter in Patients with Spina Bifida. *Urol Res Pract*. 2023 May;49(3):211-215. [IF NA, CI 0]
309. Kitta T, Kobayashi S, Togo M, Chiba H, Higuchi M, Kusakabe N, Tsukiyama M, Ouchi M, Abe-Takahashi Y, **Shinohara N**. Detrusor-Overactivity-Related Voiding in Women Mimics Bladder Outflow Obstruction and Conceals Underactivity. *Urol Res Pract*. 2023 Jul;49(4):266-270. [IF NA, CI 0]
310. Kikuchi H, Abe T, Miyake M, Miyata H, Matsumoto R, Osawa T, Nishimura N, Fujimoto K, Inokuchi J, Yoneyama T, Tomida R, Numakura K, Matsushita Y, Matsumoto K, Sato T, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, **Shinohara N**. The impact of second transurethral resection on survival outcomes in

patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy. *Jpn J Clin Oncol.* 2024 Feb 7;54(2):192-200. [IF 2.4, CI 0]

311. Kikuchi H, Maishi N, Yu L, Jia Z, Li C, Sato M, Takeda R, Ishizuka K, Hida Y, **Shinohara N**, Hida K. Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer. *Br J Cancer.* 2023 Dec 1. doi: 10.1038/s41416-023-02498-2. [IF 8.8, CI 0]
312. Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, **Shinohara N**, Uemura H. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART). *Int J Urol* 2023 Dec 18. doi: 10.1111/iju.15345. [IF 2.6, CI 0]
313. Kusakabe N, Kamijo TC, Wada N, Chiba H, **Shinohara N**, Miyazato M. Effects of low-intensity extracorporeal shock wave therapy on lipopolysaccharide cystitis in a rat model of interstitial cystitis/bladder pain syndrome. *Int Urol Nephrol.* 2024 Jan;56(1):77-86. [IF 2.0, CI 0]
314. Hirose T, Hotta K, Osawa T, Yokota I, Inao T, Tanabe T, Iwahara N, **Shinohara N**. Longitudinal mortality risks and kidney functional outcomes in Japanese living kidney donors. *Int J Urol.* 2024 Jan 19. doi: 10.1111/iju.15395. [IF 2.6, CI 0]

II. Review Articles

1. **Shinohara N**, Koyanagi T. Ras signal transduction in carcinogenesis and progression of bladder cancer: molecular target for treatment? *Urol Res.* 2002 Oct;30(5):273-81. [IF NA, CI 5]
2. Kitta T, Mitsui T, Kanno Y, Chiba H, Moriya K, **Shinohara N**. Brain-bladder control network: the unsolved 21st century urological mystery. *Int J Urol.* 2015 Apr;22(4):342-8. [IF 2.6, CI 23]
3. Osawa T, Wittmann D, Jimbo M, Keller ET, Namiki S, Abe T, **Shinohara N**, Skolarus TA. Providing prostate cancer survivorship care in Japan: Implications from the USA care

- model. *Int J Urol*. 2016 Nov;23(11):906-915.. [IF 2.6, CI 1]
4. Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, **Shinohara N**, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T, Yurikusa T, Yomiya K, Yoshida M. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. *ESMO Open*. 2016 Mar 16;1(2):e000037. [IF 7.3, CI 36]
 5. Kitta T, Kanno Y, Chiba H, Higuchi M, Ouchi M, Togo M, Moriya K, **Shinohara N**. Benefits and limitations of animal models in partial bladder outlet obstruction for translational research. *Int J Urol*. 2018 Jan;25(1):36-44. [IF 2.6, CI 18]
 6. Osawa T, Takeuchi A, Kojima T, **Shinohara N**, Eto M, Nishiyama H. Overview of current and future systemic therapy for metastatic renal cell carcinoma. *Jpn J Clin Oncol*. 2019 May 1;49(5):395-403. [IF 2.4, CI 22]
 7. Ishikawa H, Tsuji H, Murayama S, Sugimoto M, **Shinohara N**, Maruyama S, Murakami M, Shirato H, Sakurai H. Particle therapy for prostate cancer: The past, present and future. *Int J Urol*. 2019 Oct;26(10):971-979. [IF 2.6, CI 19]
 8. Kitta T, Ouchi M, Chiba H, Higuchi M, Togo M, Abe-Takahashi Y, Kusakabe N, **Shinohara N**. Animal Model for Lower Urinary Tract Dysfunction in Parkinson's Disease. *Int J Mol Sci*. 2020 Sep 7;21(18):6520. [IF 5.6, CI 3]
 9. Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, **Shinohara N**. Overview of clinical management for older patients with renal cell carcinoma. *Jpn J Clin Oncol*. 2022 Jul 8;52(7):665-681. [IF 2.4, CI 0]
 10. Osawa T, Oya M, Okanishi T, Kuwatsuru R, Kawano H, Tomita Y, Niida Y, Nonomura N, Hatano T, Fujii Y, Mizuguchi M, **Shinohara N**. Clinical Practice Guidelines for tuberous sclerosis complex-associated renal angiomyolipoma by the Japanese Urological Association: Summary of the update. *Int J Urol*. 2023 Oct;30(10):808-817. [IF 2.6, CI 0]

III. Books

1. **Shinohara N**, Togashi M, Takeuchi I, Mori T, Hamada M, Asano Y, Saitoh B, Nakanishi S, Takamatsu T, Maru A, Koyanagi T: Expression of multi-drug resistance gene product (P-glycoprotein) in normal urothelium and urothelial tumors. pp121-126 (Olsson, C.A., SIU Reports 4; Oncogenes and molecular genetics of urological tumors, Churchill Livingstone, New York) 1992
2. **Shinohara N**, Ogiso Y, Nonomura K, Koyanagi T, Kuzumaki N: Circumvention of cisplatin resistance in H-ras transformed-NIH/3T3 cells by suppressor mutant. pp221-227 (Miyazaki T, Takaku F, and Sakurada K. The Mechanism and New Approach on Drug Resistance of Cancer cells. Excerpta Medica, New York) 1993
3. **Shinohara N**, Nonomura K, Harabayashi T, Togashi M, Nagamori S, Koyanagi T: Nephron sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. pp48-49 (DeKerinion J.B, and Howards S. Year Book of Urology 1996. Mosby, St. Louis) 1996
4. Tanaka M, Sazawa A, **Shinohara N**, Kobayashi Y, Fujioka Y, Koyanagi T, Kuzumaki N.: Gelsolin gene therapy for human bladder cancer using retrovirus producer cells in nude mice. pp21-22 (Kuzumaki N. Cytoskeleton and G-proteins in the regulation of cancer, Hokkaido University Medical Librery Series Vol. 37, Sapporo) 1998
5. **Shinohara N**, Koyanagi T: Clinical aspects of kidney cancers in VHL disease. pp183-192 (Niimura M, Ohtsuka F, and Hino O. PHACOMATOSIS IN JAPAN, Epidemiology, Clinical Picture and Molecular Biology; Gann Monograph on Cancer Research, No. 46, Japan Scientific Societies Press and S.Karger AG, Tokyo) 1999

IV. Case Reports

1. Ito J, **Shinohara N**, Koyanagi T, Hanioka K. Ossifying renal tumor of infancy: the first Japanese case with long-term follow-up. Pathol Int 1998 Feb;48(2):151-9. [IF 2.2, CI 3]
2. **Shinohara N**, Takeda N, Hiraga H, Demura T, Koyanagi T. The development of a malignant fibrous histiocytoma after treatment for advanced testicular seminoma. BJU Int 1999 Feb;83(3):355-6. [IF 4.5, CI 0]
3. Haga K, **Shinohara N**, Harabayashi T, Demura T, Koyanagi T. Is serum hyaluronic acid

level useful for evaluating the clinical course of malignant mesothelioma of the tunica vaginalis? *BJU Int* 1999 Oct;84(6):729-30. [IF 4.5, CI 2]

4. Itoh T, Chikai K, Ota S, Nakagawa T, Takiyama A, Mouri G, **Shinohara N**, Yamashita T, Suzuki S, Koyanagi T, Nagashima K. Chromophobe renal cell carcinoma with osteosarcoma-like differentiation. *Am J Surg Pathol* 2002 Oct;26(10):1358-62. [IF 5.6, CI 6]
5. Harabayashi T, **Shinohara N**, Kakizaki H, Ameda K, Nonomura K, Koyanagi T. Ureteral stricture developing after partial nephrectomy with a microwave tissue coagulator: case report. *J Endourol* 2003 Dec;17(10):919-21. [IF 2.7, CI 1]
6. **Shinohara N**, Nonomura K, Ishikawa S, Seki H, Koyanagi T. Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist. *Int J Urol* 2004 Jun;11(6):432-5. [IF 2.6, CI 19]
7. Abe T, **Shinohara N**, Harabayashi T, Tsuchiya K, Suzuki S, Itoh T, Seki T, Togashi M, Nonomura K, Koyanagi T: Peritoneal carcinomatosis in refractory seminoma. *Int J Urol* 11(3), 184-186, 2004 [IF 2.6, CI 1]
8. **Shinohara N**, Harabayashi T, Suzuki S, Nakamura M, Itoh T, Nonomura K: Advanced Renal Pelvic Carcinoma Associated with Dermatomyositis. *Int J Urol* 12(10), 906-908, 2005 [IF 2.6, CI 4]
9. Sazawa A, **Shinohara N**, Harabayashi T, Abe T, Shirato H, Nonomura K: Alternative approach in the treatment of adrenal metastasis with a real-time tracking radiotherapy in patients with hormone refractory prostate cancer. *Int J Urol* 16(4), 410-412, 2009 [IF 2.6, CI 2]
10. Mimura R, Kamishima T, Kubota K, Nakano F, Yabe I, Sasaki H, Maruyama S, **Shinohara N**, Harris AA, Haga H, Shirato H, Terae S: Extramedullary plasmacytoma involving perirenal space accompanied by extramedullary hematopoiesis and amyloid deposition. *Jpn J Radiol* 28(4), 309-313, 2010 [IF 2.1, CI 2]
11. Aoyagi T, **Shinohara N**, Kubota-Chikai K, Kuroda N, Nonomura K: Long-term survival in patient with node-positive adult-onset Xp11.2 translocation renal cell carcinoma. *Urol Int* 86(4), 487-490, 2011 [IF 1.6, CI 0]

12. Akino T, **Shinohara N**, Hatanaka K, Kobayashi N, Yamamoto Y, Nonomura K. Successful penile reconstruction after multimodal therapy in patients with primitive neuroectodermal tumor originating from the penis. *Int J Urol*. 2014 Jun;21(6):619-21.. [IF 2.6, CI 2]
13. Matsumoto R, **Shinohara N**, C-Hatanaka K, Kuroda N, Tsuchiya K, Maruyama S, Abe T, Nonomura K. Concurrent occurrence of renal cell carcinoma with rhabdoid features in a married couple: a case report. *BMC Res Notes*. 2015 Jan 15;8:3. [IF 1.8, CI 0].
14. Iwami D, Ogawa Y, Fujita H, Morita K, Sasaki H, Oishi Y, Higuchi H, Hatanaka K, **Shinohara N**. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report. *Nephrology (Carlton)*. 2016 Jul;21 Suppl 1:63-6. [IF 2.5, CI 4]
15. Moriya K, Yamamoto S, Nakamura M, Nishimura Y, Nishida M, Iwai T, Kanno Y, Kitta T, **Shinohara N**. Spontaneous Shrinkage of Testicular Teratoma in a Prepubertal Child. *Urology*. 2017 May;103:e13-e14. [IF 2.1, CI 1]
16. Nishimura Y, Moriya K, Nakamura M, Kitta T, Kanno Y, Chiba H, Kon M, **Shinohara N**. Laparoscopic ureterocalicostomy for ureteropelvic junction obstruction in a 10-year-old female patient: a case report. *BMC Res Notes*. 2017 Jul 6;10(1):247. [IF 1.8, CI 3]
17. Takahashi K, Yanagi T, Kitamura S, Hata H, Imafuku K, Iwami D, Hotta K, Morita K, **Shinohara N**, Shimizu H. Successful treatment of hidradenitis suppurativa with rituximab for a patient with idiopathic carpotarsal osteolysis and chronic active antibody-mediated rejection. *J Dermatol*. 2018 May;45(5):e116-e117.[IF 3.1, CI 12]
18. Sasaki H, Iwami D, Hotta K, Morita K, Naka T, **Shinohara N**. Spontaneous reduction of native kidney size involving angiomyolipoma lesions in a kidney transplant recipient with tuberous sclerosis complex. *Int J Urol*. 2018 May;25(5):513-514. [IF 2.6, CI 2]
19. Nakamura M, Moriya K, Kon M, Nishimura Y, Kitta T, **Shinohara N**. Laparoscopic nephroureterectomy using the stoma site of cutaneous ureterostomy as a multi-channel port site in a 15-month-old child with megaureter: A case report. *Urology case reports*. 2019;27:100990. [IF 0.5, CI 0]

20. Hori K, Hirohashi Y, Aoyagi T, Taniguchi N, Murakumo M, Miyata H, Torigoe T, Abe T, **Shinohara N**, Morita K. Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report. *Exp Ther Med*. 2020 Mar;19(3):1903-1907.. [IF 2.7, CI 5]
21. Furumido J, Osawa T, Kikuchi H, Matsumoto R, Abe T, Takakuwa E, et al. Retroperitoneal extragonadal germ cell tumor without distant metastasis: a case report. *International cancer conference journal*. 2020;9(1):5-8. [IF , CI]
22. **Shinohara N**. New year's greetings. *International journal of urology* 2020;27(1):5. [IF 2.6, CI 0]
23. Yamada S, Hotta K, Takahata M, Iwami D, Sugito Y, Tanabe T, Iwahara N, **Shinohara N**. Femoral nerve palsy following kidney transplantation: A case report and review of the literature *IJU Case Rep*. 2020 Jul 29;3(6):248-251. [IF NA, CI 1]
24. **Shinohara N**. New year's greetings. *Int J Urol*. 2021 Jan;28(1):5. doi: 10.1111/iju.14479. [IF 2.6, CI 0]
25. **Shinohara N**. IJU this issue. *Int J Urol*. 2021 Aug;28(8):785. [IF 2.6, CI 0]
26. Kusakabe N, Kitta T, Chiba H, Higuchi M, **Shinohara N**. A case of pubic osteomyelitis after implantation of an artificial urinary sphincter: A case report. *Low Urin Tract Symptoms*. 2022 Jan;14(1):78-81. [IF 1.3, CI 0]
27. Iwahara N, Abe T, Nagai S, Yoshino M, Saito H, Okada H, Kikuchi H, Matsumoto R, Osawa T, **Shinohara N**. Postoperative thyroid storm after radical nephrectomy for renal cell carcinoma with inferior vena cava tumor thrombus. *IJU Case Rep*. 2021 Jul 13;4(5):330-332. [IF NA, CI 0]
28. Konno M, Osawa T, Hotta K, Shimizu A, Abe T, Matsumoto R, Kikuchi H, **Shinohara N**. Primary renal leiomyosarcoma with a tumor thrombus in the inferior vena cava. *IJU Case Rep*. 2021 Nov 19;5(1):66-69. [IF NA, CI 0]
29. Takeda H, Matsumoto R, Takakuwa E, Hori K, Moriguchi T, Yamada S, Kikuchi H, Osawa T, Abe T, **Shinohara N**. Favorable response to pembrolizumab in granulocyte colony-

- stimulating factor-producing upper urinary tract urothelial carcinoma. *IJU Case Rep.* 2021 Dec 17;5(2):108-112. [IF NA, CI 0]
30. Hayashi A, Yamamoto I, Kawabe M, Kobayashi A, Ito M, Hotta K, **Shinohara N**, Tasaki T, Yokoo T, Iwami D. CASE REPORT: Serial Cases of False-Positive Flow- Cytometry T Cell Crossmatch Associated With Anti-Blood Type Antibodies in Patients Undergoing ABO-Incompatible Kidney Transplantation. *Front Immunol.* 2022 Mar 10;13:862652. [IF 7.3, CI 0]
31. Takayanagi A, Kato F, Nozaki A, Matsumoto R, Osawa T, Kuwahara K, Matsuno Y, Asano H, Kato T, Watari H, Abe T, **Shinohara N**, Kudo K. Imaging findings of ovarian metastasis of primary renal cell carcinoma: A case report and literature review. *Radiol Case Rep.* 2022 May 5;17(7):2320-2327. [IF NA, CI 0]
32. Yamagata Y, Abe T, Iwahara N, Takada K, Hida Y, Takakuwa E, Kikuchi H, Matsumoto R, Osawa T, **Shinohara N**. Metastatic neuroendocrine carcinoma of right adrenal gland successfully treated with laparoscopic adrenalectomy after multimodal therapy. *IJU Case Rep.* 2022 Jul 29;5(6):446-450. [IF NA, CI 0]
33. **Shinohara N**. This Issue 30-5. *Int J Urol.* 2023 May;30(5):421. doi: 10.1111/iju.15186. [IF 2.6, CI 0]
34. Nonoyama S, Hotta K, Iwahara N, Tanabe T, Hirose T, Harada S, Junichi S, Nakazawa D, Shigematsu A, Otsuka T, **Shinohara N**. Use of Mixed Lymphocyte Reaction Assay to Evaluate Immune Tolerance before Kidney Transplantation with an Immunosuppression-Free Protocol following Hematopoietic Stem Cell Transplantation from the Same Donor. *Nephron.* 2023;147(10):621-626. [IF 2.5, CI 0]
35. Otsuka T, Tanabe T, Hotta K, Iwasaki S, Tsuji T, Takahashi A, Takakuwa E, **Shinohara N**, Matsuno Y. Exacerbation of Intimal Fibrosis and Endarteritis in a Kidney Transplant Recipient with Chronic Active Antibody-Mediated Rejection and COVID-19: A Case Report. *Nephron.* 2023;147 Suppl 1:41-45. [IF 2.5, CI 0]
36. Hosokawa C, Hotta K, Okamoto T, Cho Y, Hirose T, Iwahara N, Manabe A, **Shinohara N**. Prophylactic bilateral nephrectomy and preemptive kidney transplantation for Denys-Drash

syndrome prior to development of kidney failure. *Pediatr Nephrol.* 2024 Mar;39(3):905-909. [IF 3.0, CI 0]

37. Iesaka H, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Abe T, **Shinohara N**, Atsumi T. Fulminant ACTH decrease following diabetic ketoacidosis induced by immune checkpoint inhibitor combination therapy with nivolumab and ipilimumab: A case report. *Medicine (Baltimore).* 2023 Dec 22;102(51):e36664. [IF 1.6, CI 1]

V. Presentation in Meeting

特別講演

1. **Shinohara N:** Retroperitoneal laparoscopic partial nephrectomy with ice slush cooling
5th Urologic Oncology Seminar in Quangzoung, Quangzong, 2010
2. **Shinohara N:** The role of metastasectomy for patients with metastatic urological cancer
28th Korea-Japan Urological Congress, Swon, 2011
3. **Shinohara N:** Regional differences in the approach to systemic therapy for metastatic renal cell carcinoma: The Asian approach, 32th SIU annual meeting in FUKUOKA, Fukuoka, 2012

教育講演

1. **Shinohara N:** The role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma
Educational Seminar, 27th Japan-Korea Urological Congress, Kyoto, 2010
2. **Shinohara N:** “Public speaking”, Educational Lecture, Advancements in Urology 2011 (AUA/JUA joint meeting), Honolulu, 2011.
3. **Shinohara N:** “Medical Writing”, UAA Youth section, 9th Asian Endurological Conference, Kathomandu, 2011.
4. **Shinohara N:** Sorafenib-associated Hand-Foot Skin Reaction: How to deal with this adverse event?, Evening seminar, 4th Congress of the World Union of Wound Healing Societies, Yokohama, 2012
5. **Shinohara N:** Assessing the response to targeted therapies in renal cell carcinoma.
Lecture 2. AUA/JUA International affiliate society meeting New Orleans 2015.
6. **Shinohara N:** What we have been doing on immune-oncology at clinical research and practice ” Renal cell carcinoma” Educational lecture. Oncology Summit Japan Tokyo 2015

シンポジウム

1. **Shinohara N:** Psychological distress of urologic cancer patients in Japan-Based on HAD test, Special Satellite Symposium, Pan-Pacific Conference of the International Society for Quality of Life Research. Tokyo, 2001
2. **Shinohara N:** The role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Symposium 1, JUA/AUA Joint meeting in AUA 2011(Symposium 1), Washington DC, 2011
3. **Shinohara N:** Treatment of patients with metastatic bladder cancer “unfit” for cisplatin-based chemotherapy , Symposium 10 (Kidney and Bladder Cancer), 6th Japan-Asean Conference on Men’s Health & Aging, Kamakura, 2011
4. **Shinohara N:** Castration-resistant prostate cancer =Current status and future perspectives in Japan=. Symposium(Therapeutic approaches in the management of castration-resistant prostate cancer), The 29th Japan-Korea Urological Congress, Kagoshima, 2012
5. **Shinohara N:** =prognostic factor=, Symposium (Treatment strategy of RCC in Japan), The 32th SIU annual meeting in FUKUOKA, Fukuoka, 2012
6. **Shinohara N:** The role of metastasectomy for patients with metastatic renal cell carcinoma. Symposium (Contemporary Asian urology session), The 101th Japanese Urological Association annual meeting, Sapporo, 2013

一般発表

1. **Shinohara N,** Togashi M, Takeuchi I, Mori T, HamadaM, Asno Y, Saito B, Nakanishi S, Takamatsu T, Maru A, Koyanagi T: Expression of multi-drug resistance gene product (P-glycoprotein) in normal urothelium and urothelial tumors. SIU 22nd Congress, Sevilla, 1991
2. **Shinohara N,** Nonomura K, Kobayashi S, Koyanagi T: Serum and urine catecholamines in adrenal incidentaloma. 9th Japan-Korea Urological Congress, Tokyo, 1992.
3. **Shinohara N,** Ogiso Y, Nonomura K, Koyanagi T, Kuzumaki N: Circumvention of cisplatin resistance in H-ras transformed NIH/3T3 cells by suppressor mutant. International Symposium of The Mechanism and New approach on Drug Resistance of Cancer Cells, Sapporo, 1992.

4. **Shinohara N**, Nonomura K, Nagamori S, Koyanagi T: Expression of multi-drug resistance gene product (P-glycoprotein) in renal pelvic and ureter tumors. AUA 88th Annual Meeting, San Antonio, 1993.
5. **Shinohara N**, Tanaka M, Nagamori S, Takakura F, Seki T, Nonomura K, Koyanagi T, Togashi M, Maru A: Prophylactic chemotherapy with anthracycline (adriamycin, epirubicin, and THP) for primary superficial bladder cancer. 5th International Conference on Treatment of Urinary Tract Tumors with Adriamycin/ Farmorubicin, Hakone, 1993.
6. **Shinohara N**, Nonomura K, Harabayashi T, Hamada M, Kawakura K, Ueno H, Koyanagi T: Expression of proliferating cell nuclear antigen (PCNA) in normal prostate, benign prostatic hypertrophy and prostatic carcinoma. 8th SBUR annual meeting, San Francisco, 1994.
7. **Shinohara N**, Nonomura K, Tanda K, Nagamori S, Togashi M, Koyanagi T: Growth pattern of renal lesions after conservative surgery for renal cell carcinoma in von Hippel-Lindau disease. SIU 23rd Congress, Sydney, 1994.
8. **Shinohara N**, Ogiso Y, Tanaka M, Sazawa A, Demura T, Nonomura K, Koyanagi T.: Growth suppression of renal cell carcinoma cell lines by a dominant negative H-ras mutant. 1st World Congress on Basic Urological Research Organized by the ESUOE and SBUR. Rotterdam. 1995.
9. **Shinohara N**, Tanaka M, Sazawa A, Demura T, Nonomura K, Koyanagi T.: Growth suppression of renal cell carcinoma cell lines by a dominant negative H-ras mutant. AUA 91th Annual Meeting. Orlando. 1996.
10. **Shinohara N**, Nagamori S, Demura T, Nounaka O, Omuro H, Nonomura K, Koyanagi T: 5-fluorouracil and low dose interferon alpha-2a in patients with hormone-refractory prostate cancer. AUA 91th Annual Meeting. Orlando. 1996.
11. **Shinohara N**, Sazawa A, Demura T, Nonomura K, Koyanagi T: Nephron-sparing operation for renal cell carcinoma in von Hippel-Lindau disease. 2nd International VHL symposium, Honoruru, 1996

12. **Shinohara N**, Sazawa A, Demura T, Nonomura K, Koyanagi T.: Nephron-sparing surgery for renal cell carcinoma in von Hippel-Lindau disease. 13th Japan-Korea Urological Congress. Osaka. 1996.
13. **Shinohara N**, Sazawa A, Tanaka M, Demura T, Nonomura K, Koyanagi T: overexpression of ras guanine nucleotide exchange factor, son of sevenless protein, in bladder cancer. AUA 92nd Annual Meeting. New Orleans. 1997.
14. **Shinohara N**, Seki T, Demura T, Nonomura K, Koyanagi T.: Treatment strategy for renal cell carcinoma in von Hippel-Lindau disease. SIU 24th Congress. Montreal. 1997
15. **Shinohara N**, Tsuchiya K, Harabayashi T, Enami N, Tanaka M, Seki T, Demura T, Nonomura K, Koyanagi T: Nephron sparing surgery in patients with localized small renal cell carcinoma. SIU 24th Congress. Montreal. 1997
16. **Shinohara N**, Demura T, Nonomura K, Koyanagi T: Treatment of renal cell carcinoma in von Hippel-Lindau disease. UICC Symposium: Familial Cancer and Prevention, Kobe. 1997
17. **Shinohara N**, Harabayashi T, Sazawa A, Tanaka M, Kobayashi Y, Demura T, Koyanagi T: The significance of C3G, one of ras guanine nucleotide exchange factors, in the proliferation of human bladder cancer cell lines. AUA 93rd Annual Meeting. San Diego. 1998
18. **Shinohara N**, Watanabe T, Sazawa A, Harabayashi T, Kuzumaki N, Koyanagi T: The significance of ras guanine nucleotide exchange reaction in bladder cancer cell lines, 4th International Symposium; Impact of biotechnology on cancer prediction, prevention and treatment, Nice. 1998
19. **Shinohara N**, Harabayashi T, Sato S, Sakamoto K, Hioka T, Demura T, Koyanagi T: The impact of nephron-sparing surgery on quality of life in patients with localized kidney cancer, AUA 94th Annual Meeting, Dallas, 1999.
20. **Shinohara N**, Watanabe T, Sazawa A, Harabayashi T, Koyanagi T, Kuzumaki N: In vivo adenovirus-mediated gene therapy of human bladder cancer in orthotopic model by the dominant negative ras mutant, AUA 95th Annual Meeting, Atlanta, 2000

21. **Shinohara N**, Watanabe T, Sazawa A, Harabayashi T, Koyanagi T, Kuzumaki N:
Adenovirus-mediated gene therapy of human bladder cancer in orthotopic model by the dominant negative ras mutant N116Y, 5th International Symposium on Predictive Oncology & Therapy; Impact of Biotechnology on Cancer Diagnosis & Prognostic Indicators, Geneva, 2000
22. **Shinohara N**, Harabayashi T, Sazawa A, Kitamura K, Shirato H, Koyanagi T: Conformal radiotherapy with or without concurrent infusion chemotherapy for locally-advanced bladder cancer: results of a pilot study. Gated Radiotherapy 2000, Sapporo, 2000
23. **Shinohara N**, Harabayashi T, Koyanagi T: Stage-specific followup protocol after radical nephrectomy for renal cell carcinoma: Could we follow the T1b patients by a same followup protocol of T1a patients? AUA 97th Annual Meeting, Atlanta, 2002
24. **Shinohara N**: Clinical features and prognosis of renal cell carcinoma in Japanese patients with von Hippel-Lindau disease. International VHL conference, Kohchi, 2004
25. **Shinohara N**, Nishi M, Shibata Y, Minowada S, Murakumo M, Furuno T, Yamanaka H, Koyanagi T: A new portable flexible cystoscope with bullet-tip: Is this less uncomfortable than standard flexible cystoscope? 27th Congress of the Societe Internationale'd Urologie, Hawaii, 2004
26. **Shinohara N**, Suzuki S, Abe T, Murakumo M, Nagamori S, Mitsunashi K, Harabayashi T, Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide and nedaplatin (PIN regimen) in patients with urothelial cancer who have received prior cisplatin-based therapy. 20th European Association of Urology Congress, Istanbul, 2005
27. **Shinohara N**, Suzuki S, Harabayashi T, Murakumo M, Mitsunashi K, Demura T, Nagamori S, Nonomura K: Combination chemotherapy paclitaxel, ifosfamide and nedaplatin in the treatment for advanced or recurrent urothelial cancer. 41st ASCO annual meeting, Orlando 2005
28. **Shinohara N**, Suzuki S, Abe T, Sazawa A, Harabayashi T, Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide and nedaplatin in patients with urothelial cancer who have received prior cisplatin-based therapy. 100th AUA Annual meeting, San Antonio

2005

29. **Shinohara N**, Harabayashi T, Suzuki S, Nagao K, Seki H, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Matsuyama H, Naito K, Nonomura K: Combination chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy; advanced report. 21th EAU Annual Congress Paris 2006
30. **Shinohara N**, Harabayashi T, Suzuki S, Nagao K, Nagamori S, Matsuyama H, Naito K, Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. 42th ASCO annual meeting Atlanta 2006
31. **Shinohara N**, Harabayashi T, Sazawa A, Abe T, Takeuchi I, Kumagai A, Kashiwagi A, Nagamori S, Nonomura K: Positive impact of nephron-sparing surgery on long-term postoperative quality of life in patients with T1 renal cell carcinoma. 101th AUA annual meeting Anaheim 2007
32. **Shinohara N**, Harabayashi T, Sazawa A, Watarai Y, Kumagai A, Murakumo M, Sakashita S, Mori T, Kanagawa K, Nonomura K: Meloxicam, a selective cyclooxygenase-2 (COX-2) inhibitor, enhances the response to interferon- α 2a in metastatic renal cell carcinoma: a phase II study on efficacy and toxicity. ASCO annual meeting Chicago 2007
33. **Shinohara N**, Harabayashi T, Sazawa A, Nonomura K, Hokkaido Immunotherapy Research Group: Combination therapy of meloxicam, a COX-2 inhibitor, and interferon alfa in metastatic renal cell carcinoma. ASCO-GU meeting San Francisco 2008.
34. **Shinohara N**, Kumagai A, Kanagawa K, Watarai Y, Murakumo M, Sazawa A, Abe T, Harabayashi T, Nonomura K, Hokkaido Immunotherapy Research Group: Phase II trial of meloxicam, a COX-2 inhibitor, and interferon alfa in patients with metastatic renal cell carcinoma. ASCO 44th annual meeting Chicago 2008.
35. **Shinohara N**, Sazawa A, Uchino H, Abe T, Maruyama S, Morita K, Sato S, Suzuki S, Harabayashi T, Nonomura K: New treatment approach for poor-risk patients with metastatic renal cell carcinoma: Is upfront interferon-alfa therapy feasible on the identification of appropriate candidate for cytoreductive nephrectomy?. 5th ASCO-GU meeting Orlando

2009.

36. **Shinohara N**, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A randomized multi-center phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. 47th ASCO annual meeting Chicago 2011.
37. **Shinohara N**, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, Sazawa A, Oba K, Nonomura K: Prognosis of renal cell carcinoma patients with disease recurrence following nephrectomy for localized disease. 8th ASCO-GU meeting San Francisco 2012.
38. **Shinohara N**, Abe T, Maruyama S, Sazawa A, Nonomura K: Risk classification to predict survival after cytoreductive nephrectomy in patients with metastatic renal cell carcinoma. 107th AUA annual meeting in Atlanta Atlanta 2012
39. **Shinohara N**, Maruyama S, Shimizu S, Nonomura K, Shirato H: Longitudinal comparison of quality of life after real-time tumor-tracking intensity-modulated radiation therapy and radical prostatectomy in patients with localized prostate cancer. 3rd International conference on real-time tumor-tracking radiation therapy with 4D molecular imaging technique Sapporo 2013
40. **Shinohara N**, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A randomized multi-center phase II trial on efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. The 49th ASCO Annual meeting Chicago 2013.

その他

1. **Shinohara N**, Suzuki S, Harabayashi T, Murakumo M, Mitsuhashi K, Demura T, Nagamori S, Nonomura K: Combination chemotherapy with paclitaxel, ifosfamide, and nedaplatin in the treatment for advanced or recurrent urothelial cancer. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings Vol 23, 2007: 5105
2. **Shinohara N**, Harabayashi T, Suzuki S, Nagao K, Nagamori S, Matsuyama H, Naito K, Nonomura K: Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy. J Clin Oncol, 2006

ASCO Annual Meeting Proceedings Vol 24, 2006: 236

3. **Shinohara N**, Harabayashi T, Sazawa A, Nonomura K, Watarai Y, Kumagai A, Murakumo M, Kanagawa K, Sakashita S: Combination therapy of meloxicam, a selective COX-2 inhibitor, and interferon alfa in metastatic renal cell carcinoma: A phase II study on efficacy and toxicity. *J Clin Oncol*, 2007 ASCO Annual Meeting Proceedings Vol 25, 2007: 5105
4. **Shinohara N**, Abe T, Sazawa A, Nonomura K: Phase II trial of meloxicam, a COX-2 inhibitor, and interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol*, 2008 ASCO Annual Meeting Proceedings Vol 26, 2008: 16003
5. **Shinohara N**, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A randomized multicenter phase II trial on efficacy of high-slip skin care pad for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. *J Clin Oncol*, 2011 ASCO Annual Meeting Proceedings Vol 29, 2011: TPS233
6. **Shinohara N**, Nonomura N, Kimura G, Eto M, Minami H, Yamazaki N, Naito S: A randomized multicenter phase II trial on efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma. *J Clin Oncol*, 2013 ASCO Annual Meeting Proceedings Vol 31, 2013: TPS233 31, 2013: 9623
7. **Shinohara N**: Editorial Comment to Features, risk factors and clinical outcome of "very late" recurrences after surgery for localized renal carcinoma: A retrospective evaluation of a cohort with a minimum of 10 years of follow up. *Int J Urol*. 2016; 23(1):40-41. [5y-IF: 1.932]

VI 日本語ガイドライン等

1. 腎癌診療ガイドライン 2007年版 金原出版 日本泌尿器科学会編（作成委員）
2. 腎癌診療ガイドライン 2011年版 金原出版 日本泌尿器科学会編（作成委員）
3. 精巣腫瘍診療ガイドライン 2015年版 金原出版 日本泌尿器科学会編（作成委員）
4. 結節性硬化症に伴う腎血管筋脂肪種診療ガイドライン 2016年版 金原出版 日本泌尿器科学会・日本結節性硬化症学会、編（作成委員）
5. 結節性硬化症に伴う腎血管筋脂肪種診療ガイドライン 2023年版 メディカルレビュー社 日本泌尿器科学会・日本結節性硬化症学会、編（作成委員長）
6. 腎盂・尿管癌診療ガイドライン 2023年版 医学図書出版 日本泌尿器科学会編（評価委員長）
7. 骨転移診療ガイドライン 第1版 南江堂 日本臨床腫瘍学会、編（作成委員）
8. フォン・ヒッペル・リンドウ(VHL)病診療ガイドライン 「フォン・ヒッペル・リンドウ病の病態調査と診断治療系確立の研究」班 中外医学社（研究分担者）
9. 腎癌取り扱い規約 第4版(2011年4月) 金原出版 日本泌尿器科学会・日本病理学会・日本医学放射線学会編（作成委員）
10. 腎癌取り扱い規約 第5版(2020年12月) メディカルレビュー社 日本泌尿器科学会・日本病理学会・日本医学放射線学会編（作成委員長）
11. 精巣腫瘍取り扱い規約 第4版(2018年8月) 金原出版 日本泌尿器科学会・日本病理学会・日本医学放射線学会・日本臨床腫瘍学会、編（作成委員）
12. がん治療認定医教育セミナー 第8版 一般社団法人日本がん治療認定医機構教育委員会
13. がん治療認定医教育セミナー 第9版 一般社団法人日本がん治療認定医機構教育委員会

14. がん治療認定医教育セミナー 第10版 一般社団法人日本がん治療認定医機構教育委員会

VII 受賞・表彰・研究費


名目	受賞年月	選考機関	受賞名	受賞金額	題名
助成金	1995/11/2	秋山記念生命科学振興財団	助成金	900,000 円	ヒト腎細胞がんに対する N116Y を用いた遺伝子治療の基礎的研究
助成金	2000/4/11	財団法人聖ルカ・ライフサイエンス研究所	助成金	500,000 円	泌尿器科がん患者における精神症状の評価と、それに基づく看護アプローチの樹立に関する研究
表彰	2008/10/31	第46回日本癌治療学会総会	優秀演題		遠隔転移を有する腎がん患者に対する天然型インターフェロン、メロキシカム併用療法の意義
表彰	2012/6/16	第9回泌尿器科再建再生研究会	研究会賞		前腕遊離皮弁を用いた陰茎形成術により陰茎の再建に成功した陰茎原発 primitive neuroectodermal tumor の1例
表彰	2013/10/24-26	第51回日本癌治療学会総会	優秀演題		Sorafenib 関連手足皮膚反応に対する高すべり性スキンケアパッドの有用性の検討
表彰	2019/10/5	北海道医師会	北海道医師会賞		進行性腎細胞がんにおける予後因子の解析と全身療法の適正使用に関する研究
表彰	2019/10/5	北海道	北海道知事賞		進行性腎細胞がんにおける予後因子の解析と全身療法の適正使用に関する研究
表彰	2021/4/21	厚生労働省	厚生労働大臣感謝状		令和2年度臓器移植対策推進功労者

VIII. 医局の変遷


医局スタッフ(2014-2023年度)

役職	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
教授	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄	篠原信雄
准教授				守屋仁彦	守屋仁彦	安部崇重	安部崇重	安部崇重	安部崇重	安部崇重
特任准教授								橋田岳也		
講師	森田 研 守屋仁彦	森田 研 守屋仁彦	丸山 覚 守屋仁彦	丸山 覚 守屋仁彦	岩見大基 守屋仁彦	岩見大基 守屋仁彦	大澤崇宏 堀田記世彦	大澤崇宏 堀田記世彦	大澤崇宏 堀田記世彦	大澤崇宏 堀田記世彦
講師		安部崇重	安部崇重	安部崇重	安部崇重	堀田記世彦	堀田記世彦	堀田記世彦	堀田記世彦	堀田記世彦
講師		橋田岳也	橋田岳也	橋田岳也	橋田岳也	橋田岳也	橋田岳也			
特任講師									松本隆児	松本隆児
助教	三井貴彦							菊池 央	広瀬貴行	広瀬貴行
助教	安部崇重	岩見大基	岩見大基	岩見大基	松本隆児	松本隆児	松本隆児	松本隆児	宮田 遥	宮田 遥
助教	丸山 覚	丸山 覚	堀田記世彦	堀田記世彦	堀田記世彦	千葉博基	千葉博基	千葉博基	千葉博基	千葉博基
助教	土屋邦彦	土屋邦彦	菅野由岐子	菅野由岐子	垣淵由岐子	今 雅史	今 雅史	今 雅史	今 雅史	今 雅史
助教	橋田岳也	中村美智子	中村美智子	中村美智子	中村美智子	中村美智子	中村美智子	樋口まどか	樋口まどか	樋口まどか
助教	宮島直人	宮島直人	宮島直人	大澤崇宏	大澤崇宏	大澤崇宏	田邊 起	田邊 起	岩原直也	岩原直也
特任助教	佐藤早基子	村井祥代	村井祥代	村井祥代	村井祥代	村井祥代	村井祥代	村井祥代	村井祥代	村井祥代
										6か月クーリング村井祥代
							三井貴彦 (山梨大学)			
他大学教授							岩見大基 (自治医大 腎泌尿器外科)		守屋仁彦(自治医大 とちぎこども医療セン ター)	


専攻医数(入局者数;2014-2024年度)



医局員数(教授以外;2014-2023年度)



手術件数(2014-2023年度)



手術件数(2014-2023年度)

